   
 
 A5336  
 
 
A Randomized, Pilot  Study of Ruxolitinib in Antiretroviral -Treated HIV -Infected 
Adults  
 
 
A Multicenter Trial of the AIDS Clinical Trials Group (ACTG)  
 
 
 
Sponsored by:  
  
The National Institute of Allergy  
and Infectious Diseases  
 
 
 
IND # 125,580  
 
 
 
The ACTG  End-Organ Disease and  
Inflammation Transformative Science Group  Chair : Peter Hunt , MD, Chair  
 
Protocol Co-Chair s: Vincent Marconi , MD 
 Jeffre y Lennox, MD  
 
Protocol Co- Vice Chair s:   Steve Deeks, MD  
 Carlos Del Rio, M D 
 
DAIDS Clinical Representati ves: Randall  L. Tressler, MD  
 Grace Chen, MD, MPH  
 
Clinical Trials Specialist : Suria Yesmin, BS, CCRP   
 
 
 
FINAL  Version 2.0 
May 21, 201 5 
A5336  
  FINAL  Version 2.0 
  05/21/15 
   
 
 CONTENTS  
  Page  
 
SITES PARTICIPATING IN  THE STUDY  ................................ ................................ ....................  4 
PROTOCOL TEAM ROSTER  ................................ ................................ ................................ ..... 5 
STUDY MANAGEMENT  ................................ ................................ ................................ .............  8 
GLOSSARY OF PROTOCOL -SPECIFIC TERMS  ................................ ................................ ..... 10 
SCHEMA  ................................ ................................ ................................ ................................ .. 11 
1.0 HYPOTHESES AND STUDY OBJECTIVES ................................ ................................ .. 14 
1.1 Hypotheses  ................................ ................................ ................................ ........  14 
1.2 Primary Objectives  ................................ ................................ .............................  14 
1.3 Secondary Objectives  ................................ ................................ ........................  14 
1.4 Exploratory Objective  ................................ ................................ .........................  15 
2.0 INTRODUCTION  ................................ ................................ ................................ ...........  15 
2.1 Background  ................................ ................................ ................................ ........  15 
2.2 Rationale  ................................ ................................ ................................ ...........  17 
3.0 STUDY DESIGN  ................................ ................................ ................................ ...........  34 
4.0 SELECTION AND ENROLLMENT OF PARTICIPANT S ................................ ...............  35 
4.1 Inclusion Criteria  ................................ ................................ ................................  35 
4.2 Exclusion Criteria  ................................ ................................ ...............................  37 
4.3 Study Enrollment Procedures ................................ ................................ .............  39 
4.4 Coenrollment Guidelines  ................................ ................................ ....................  40 
5.0 STUDY TREATMENT  ................................ ................................ ................................ ... 40 
5.1 Regimens, Administration, and Duration  ................................ ............................  40 
5.2 Study Product Formulation and Preparation  ................................ .......................  40 
5.3 Pharmacy: Pro duct Supply, Distribution, and Accountability  ..............................  40 
5.4 Concomitant Medications  ................................ ................................ ...................  41 
6.0 CLINICAL AND LABORATORY EVALUATIONS  ................................ ...........................  42 
6.1 Schedule of Events  ................................ ................................ ............................  42 
6.2 Timing of Evaluations  ................................ ................................ .........................  44 
6.3 Instructions for Evaluations  ................................ ................................ ................  46 
7.0 CLINICAL MANAGEMENT ISSUES  ................................ ................................ ..............  54 
7.1 Toxicity  ................................ ................................ ................................ ..............  54 
7.2 Othe r Toxicities  ................................ ................................ ................................ .. 55 
7.3 Other Diseases  ................................ ................................ ................................ .. 57 
7.4 Pregnancy ................................ ................................ ................................ ..........  57 
7.5 Confirmed Virologic Failure  ................................ ................................ ................  57 
A5336  
  FINAL  Version 2.0 
  05/21/15 
CONTENTS (Cont’d)  
Page  
 
8.0 CRITERIA FOR DISCONTINUATION  ................................ ................................ ...........  58 
8.1 Premature Treatment Discontinuation  ................................ ................................  58 
8.2 Premature Study Discontinuation  ................................ ................................ ....... 58 
9.0 STATISTICAL CONSIDERATIONS  ................................ ................................ ...............  58 
9.1 General Design Issues  ................................ ................................ .......................  58 
9.2 Objectives  ................................ ................................ ................................ ..........  59 
9.3 Randomization and Stratification  ................................ ................................ ........  60 
9.4 Sample Size and Accrual  ................................ ................................ ...................  60 
9.5 Monitoring  ................................ ................................ ................................ ..........  62 
9.6 Analyses  ................................ ................................ ................................ ............  62 
10.0  PHARMACOLOGY PLAN  ................................ ................................ ..............................  64 
10.1  Pharmacology Objectives  ................................ ................................ ..................  64 
10.2  Pharmacology Study Design  ................................ ................................ ..............  64 
10.3  Primary and Secondary D ata, Modeling, and Data Analysis  ..............................  65 
10.4  Anticipated Outcomes  ................................ ................................ ........................  66 
11.0  DATA COLLECTION AND MONITORING AND ADVERSE EVENT REPORTING  ........  66 
11.1  Records to Be Kept  ................................ ................................ ............................  66 
11.2  Role of Data Management  ................................ ................................ .................  66 
11.3  Clinical Site Monitoring and Record Availability  ................................ ..................  66 
11.4  Expedited Adverse Event Reporting to DAIDS  ................................ ...................  66 
12.0 PARTICIPANT S ................................ ................................ ................................ ............  68 
12.1  Institutional Review Board (IRB) Review and Informed Consent  ........................  68 
12.2  Participant  Confidentiality  ................................ ................................ .................  68 
12.3  Study Discontinuation  ................................ ................................ ........................  68 
13.0  PUBLICATION OF RESEARCH FINDINGS  ................................ ................................ .. 68 
14.0  BIOHAZARD CONTAINMENT  ................................ ................................ ......................  68 
15.0  REFERENCES  ................................ ................................ ................................ ..............  69 
 
APPENDIX I: SAMPLE INFORMED CONSENT  
 
 4 A5336  
FINAL  Version 2.0 
  05/21/15 
 
SITES  PARTICIPATING  IN THE STUDY  
 
A5336 is open to all U.S. ACTG clinical research sites (CRS).  
 
 
 
 
 
 
 5 A5336  
FINAL  Version 2.0 
  05/21/15 
 PROTOCOL TEAM ROSTER  
 
Co-Chairs  
Vincent Marconi, MD  
Division of Infectious Diseases  
Emory University School of Medicine  
341 Ponce de Leon Avenue  
Atlanta, GA 30308  
Phone : (404) 616 -2493  
FAX:    (404) 616 -0592  
E-Mail: vcmarco@emory.edu  
 
Jeffrey Lennox, MD  
Division of Infectious Diseases  
Emory University School of Medicine  
341 Ponce de Leon Avenue  
Atlanta, GA 30322  
Phone : (404) 251 -8784 
FAX:     (404) 616-0592  
E-Mail:  jlennox@emory.edu  
 
Vice Chairs  
Steve Deeks, MD  
UCSF School of Medicine  
SFGH Building  80 
995 Potrero Avenue  
San Francisco, CA  94110  
Phone: (415) 476 -4082 Ext.  330 
FAX:     (416) 47 6-6953  
E-Mail:  sdeeks@php.ucsf.edu  
 
Carlos D el Rio, MD  
Division of Infectious Diseases  
Emory University School of Medicine  
1518 Clifton Road, NE Room 7011  
Atlanta, GA  30322  
Phone: (404) 727 -1557  
FAX:     (404) 7 27-1278  
E-Mail:  cdelrio@emory.edu  
 
DAIDS Clinical Representative s 
Randall L. Tressler , MD 
TRP, DAIDS, NIAID, NIH  
5601 Fishers Lane, 9E47  
Rockville, MD  20852  
Phone:  (240) 627-3072   
FAX:     (301) 435 -9282  
E-Mail:  randall.tressler@nih.gov  DAIDS Clinical Representative s (Cont’d)  
Grace Chen, MD, MPH  
TRP, DAIDS, NIAID, NIH  
5601 Fishers Lane  
Room 9E57 MSC 9 832 
Rockville, MD  20892  
Phone: (240) 292 -4836  
E-Mail:  grace.chen@nih.gov  
 
Clinical Trials Specialist  
Suria Yesmin,  BS, CCRP  
ACTG Network Coordinating Center  
Social & Scientific Systems , Inc.  
8757 Georgia Avenue, 12th Floor  
Silver Spring, MD  20910 -3714  
Phone: (301) 628 -3493  
FAX:     (301) 628 -3302  
E-Mail:  syesmin@s -3.com  
 
Statis tician  
Carlee Moser , PhD  
Statistical & Data Analysis Center  
Center for Biostatistics in AIDS Research  
Harvard T. H. Chan School of Public Health  
FXB Building, Room 529A 
651 Huntington Avenue  
Boston, MA  02115  
Phone: (617) 432 -2526  
FAX:     (617) 432 -3163  
E-Mail:  cmoser@sdac.harvard.edu  
 
Data Manager  
David Nichols, BS  
Frontier Science and Technology Research 
Foundation , Inc.  
4033 Maple Road  
Amherst , NY  14226  
Phone:  (716) 834 -0900  Ext. 7359  
FAX:      ( 716) 834 -8432  
E-Mail:   nichols @fstrf.org  
 
 
 
 
 
 
 6 A5336  
FINAL  Version 2.0 
 PROTOCOL TEAM ROSTER (Cont'd)  05/21/15 
 
DAIDS Pharmacist  
Ana Martinez, RPh  
Pharmaceutical Affairs Branch  
DAIDS, NIAID , NIH  
5601 Fishers Lane, 9D32  
Rockville, MD 20852  
Phone:  ( 301) 435-3734  
FAX:      (301) 402 -1506  
E-Mail:   amartinez@niaid.nih.gov  
 
Immunologist  
Michael Lederman, MD  
Case Western Reserve University  
The Foley Building, Room 401 -A 
2061 Cornell Road  
Cleveland , OH 44106 -5083  
Phone: ( 216) 844 -8786  
FAX:     ( 216) 844 -5523  
E-Mail:  mxl6@case.edu  
 
Pharmacologist  
Charles W. Flexner, MD  
Division of Clinical Pharmacology  
Johns Hopkin s University  
600 North Wolfe Street -Osler 527  
Baltimore , MD 21287 -5554  
Phone : (410) 955 -9712   
FAX:     (410) 614 -9978  
E-Mail:  flex@jhmi.edu   
 
Virologist  
Athe Tsibris, MD  
65 Landsdowne Street, Room 422  
Cambridge, MA 02139  
Phone: ( 617) 417 -1162   
             (617) 768 -8352  
FAX:     ( 617) 768 -8738  
E-Mail: atsibris@partners.org  
 
Investigators  
Christina Gavegnano, PhD  
Veterans Administration Medical Center  
1760 Haygood Drive, NE  
Atlanta, GA 30322  
Phone:  (404) 727 -1414  
E-Mail: cgavegn@emory.edu  
 
 Investigators (Cont’d)  
Selwyn Hurwitz, PhD  
Veterans Administration Medical Center  
1760 Haygood Drive, NE  
Atlanta, GA 30322  
Phone:  (404) 727 -1414  
FAX:      (404) 922 -0397  
E-Mail:   shurwit@emory.edu  
 
Raymond F. Schinazi, PhD, DSc  
Emory Center for AIDS Research  
1760 Haygood Drive, Room E420  
Atlanta, GA 30322  
Phone :  (404) 727 -1414   
FAX:      ( 404) 727 -1330  
E-Mail:   rschina@emory.edu  
 
Javier Valencia, MD  
Asociacion Civil Impacta Salud y Educacion  
Av. Almirante Miguel Grau No. 1010  
Lima 4  
PERU  
Phone:   +(51-1) 206 -7800 Ext . 209 
E-Mail:  jvalencia@im pactaperu.org  
 
Sara Gianella Weibel, MD  
Center for Aids Research (CFAR)  
University of California San Diego  
9500 Gilman Drive  
La Jolla, CA 92093 -0679  
Phone:  (858) 552 -8585 Ext. 7193  
E-Mail:  gianella@ucsd.edu  
 
Field Representative  
Jay (John) Dwyer, RN, BA  
SFGH Positive Health Program  
995 Potrero Avenue, Ward 84  
San Francisco , CA 94110 -2897  
Phone:   (415) 476-4082 Ext.  353 
FAX:      (415) 476-6736  
E-Mail:   jdwyer@php.ucsf.edu  
 
 
 
 
 
 
 
 7 A5336  
FINAL  Version 2.0 
 PROTOCOL TEAM ROSTER (Cont'd)  05/21/15 
 
Laboratory Technologist  
Carmen M. Irizarry, MT  
Medical Science Campus  
Pathology 606 -A 
San Juan, PR  00935  
Phone:  ( 787) 758 -5815  
FAX:      (787) 751 -9210  
E-Mail:   lab053.rcm@upr.edu  
 
Community Scien tific Subcommittee (CSS)  
Representative s 
Graig Cote  
765 Kenwick Road, Apt #C  
Columbus, OH 43209  
Phone:  (614) 297 -5667  
FAX:      (614) 293 -4556  
E-Mail:   graigcote@yahoo.com  
 
William (Royce) Hardin  
University of North Carolina AIDS CRS  
1005 Iredell Street  
Durham ,  NC 27705  
Phone:  ( 919) 286 -4969  
E-Mail:   wrhardin05@gmail.com  
 
Laboratory Data Manager  
Adam Manzella , MA 
Frontier Science and Technology Research 
Foundation , Inc.  
4033 Maple Road  
Amherst , NY  14226  
Phone:   (716) 834 -0900 Ext. 74 18 
E-Mail:   manzella@fstrf.org  
 
 8 A5336  
FINAL  Version 2.0 
  05/21/15 
 STUDY MANAGEMENT  
 
All questions concerning this protocol should be sent to actg.corea5336@fstrf.org  via e -mail. 
The appropriate team member will respond with a "cc" to actg.corea 5336 @fstrf.org.  A response 
should generally be received within 24 hours (Monday -Friday).  
 
Protocol E-mail Group  
Sites should contact the Computer Support Group at the Data Manag ement Center (DMC) as 
soon as possible to have the relevant personnel at the site added to the actg.protA 5336  e-mail 
group. Include the protocol number in the e -mail participant  line.  
 Send an e -mail message to actg.user.support@fstrf.org   
 
Clinical Management  
For questions concerning entry criteria, toxicity management, concomitant medications, and 
coenrollment, contact the protocol team .  
 Send an e -mail message to actg.corea5336@fstrf.org . Include the protocol number, patient 
identification number (PID), and a brief relevant history.  
 
Laboratory  
For questions specifically related to immunologic, virologic, or pharmacol ogic laboratory tests, 
contact the  protocol immunologist, virologist , or pharmacologist .  
 Send an e -mail message to actg.corea5336@fstrf.org  (ATTN: Michael Lederman, Athe  
Tsibris and Charles Flexner ). 
 
Data M anagement  
For nonclinical questions about transfers, inclusion/exclusion criteria, case report forms (CRF s), 
the CRF schedule of events, randomization/registration, delinquencies, and other data 
management issues, contact the data manager. CRFs can be down loaded from the FS TRF 
website at www.fstrf.org.  
 For transfers, reference the Patient Transfer from Site to Site SOP 1 19, and contact Dave 
Nichols  directly.  
 For other questions, s end an e -mail message to  actg. corea5336@fstrf.org  (ATTN : Dave 
Nichols ).   
 Include the protocol number, PID, and a detailed question.  
 
Randomizatio n  
For randomization /participant  registration  questions or problems and study identification 
number SID lists .  
 Send an e -mail message to rando.support@fstrf.org . Call the Statistical and Data Analysis 
Center ( SDAC )/DMC Randomization Desk at 716-834-0900 x7301 .    
 
Computer and Screen Problems   
Contact the SDAC/DMC programmers.  
 Send a n e-mail message to  actg.support@fstrf.org   or call 716-834-0900 x 7302 . 
 
 9 A5336  
FINAL  Version 2.0 
 STUDY MANAGEMENT (Cont'd)  05/21/15 
 
Protocol Document Questions  
For questions concerning the protocol document, contact the clinical trials specialist.  
 Send an e -mail message to actg.corea5336@fstrf.org  (ATTN: Suria Yesmin ). 
 
Copies of the Protocol  
To request a hard cop y of the protocol, send  an email message to  ACTGNCC@s -3.com  (ATTN: 
Diane Delgado) . Electronic copies can be downloaded from the ACTG Web site 
(https://www.actgnetwork.org ). 
 
Product  Package Inserts and/or Investigator Brochures  
To request copies of product  package inserts or investigator brochu res, contact the DAIDS 
Regulatory Support  Center (R SC) at RIC@tech -res.com  or call 301-897-1708 . 
 
Protocol Registration  
For protocol registration questions , send an e -mail message to Protocol@tech -res.com  or call 
301-897-1707 .  
 
Protocol Activatio n 
For questions related to protocol activation, contact the clinical trials specialist  (Suria 
Yesmin, syesmin@s -3.com ) or ACTG Site Coordination group at actgsitecoordination@s -
3.com .  
 
Study Product  
For questions or problems regarding study produ ct, dose, supplies, records, and returns, call 
Ana Martinez,  protocol pharmacist, at 301-435-3734 .  
 
Study Drug Orders  
Call the Clinical Research Products Management Center (CRPMC) at 301-294-0741.  
 
IND (Investigational New Drug)  Number or Questions  
The I ND number will be available on the PSWP within 30 days of the submission to the FDA. 
For any questions related to the IND submission, c ontact the  DAIDS  RSC at Regulatory@tech -
res.com  or call 301-897-1706.  
 
Expedited Adverse Event  (EAE) Reporting/ Questions   
Contact DAIDS through the R SC Safety Office at DAIDSRSCSafetyOffice@tech -res.com  or call 
1-800-537-9979  or 301-897-1709; or fax 1-800-275-7619 or 301-897-1710.  
 
Phone Calls  
Sites are responsible for documenting any phone calls made to A5336 team members.  
 Send an e -mail to actg.corea5336@fstrf.org . 
 
Protocol -Specific Web Page  
Additional information about managem ent of the protocol  can be found on the protocol -specific 
web page  (PSWP) . 
 10 A5336  
FINAL  Version 2.0 
  05/21/15 
GLOSSARY OF PROTOCOL -SPECIFIC TERMS  
 
3TC  lamivudine  
ABC  abacavir  
ACR   American College of Rheumatology  
ALT   alanine aminotransferase  
AML  acute myeloid leukemia  
ANC   absolute n eutrophil count 
AST   aspartate aminotransferase  
ATP  adenosine triphosphate  
BBB  blood brain b arrier  
CMV   cytomegalovirus  
CNS   central n ervous  system  
CSF  cerebrospinal fluid 
CVD   cardiovascular disease  
CWRES  conditional weighted residual  
EBV  Epstein Barr  virus  
EFV  efavirenz  
ET  essential thrombocythemia  
FOCE INT  first order conditional estimation with - interactions  
FTC  emtricitabine  
G-CSF  granulocyte colony stimulating factor  
GM-CSF granulocyte -macrophage colony stimulating factor  
HBM   human b iological materials  
HHV   human herpes viruses  
HSV  herpes simplex viruses  
INSTI   integrase strand t ransfer inhibitors  
JAK  Janus activating kinase  
LTBI   latent tuberculosis infection  
LTR  long terminal repeat sequences  
mCSF   macrophage colony stimulating factor  
MDM   monocyte -derived macrophages  
NHP   non-human primate  
NNRTI s nonnucleoside reverse transcriptase inhibitors   
NRTI s  nucleoside reverse transcriptase i nhibitors  
PML  progressive m ultifocal leukoencephalopathy  
PV   polycythemia v era  
RA  rheumatoid arthritis  
ROS   reactive oxygen s pecies  
SAE  serious adverse e vents  
SIV  simian immunodeficiency virus  
STAT   signal transducer and activator of t ranscription   
SUSARs  serious unexpected serious adverse  reaction s 
TCR  T cell receptor  
TDF  tenofovir  
TNF-α  tumor necrosis factor alpha  
Tscm  stem -cell memory T -cells 
  
 11 A5336  
FINAL  Version 2.0 
  05/21/15 
SCHEMA  
A5336  
 
A Randomized, Pilot Study of Ruxolitinib in Antiretroviral -Treated HIV -Infected Adults  
 
DESIGN  This is a multi -center, randomi zed, open -label, two arm (phase II a) study . 
Eligible participant s on select antiretroviral therapy (ART) with  virologic 
suppression will be randomized to receive ruxolitinib  or no study treatment  
to measure safet y and tolerability and to determine whether there are 
changes in systemic immune activation and inflammation  after 5 weeks of 
treatment with ruxolitinib .   
 
DURATION  Participant s will participate in the  study for up to 12 weeks after 
randomization.  
 
SAMPLE SIZE  A total of 60 participant s will be enr olled in the study (40 on ruxolitinib 
[Arm A]; 20 on no study treatment [Arm B]). 
  
 The study aims to enroll at least 1 5 participant s on efavirenz ( EFV) in 
order to have at least 8 ruxolitinib -treated participant s to evaluate 
pharmacokinetic (PK)  interact ions with EFV.  
 
POPULATION  HIV-1 infected males  and females ≥  18 and < 75 years of age on stable 
ART for at least 12 weeks  prior to study entry  containing either 
tenofovir /emtricitabine ( TDF/ FTC) or ab acavir /lamivudine ( ABC/ 3TC) plus a  
nonnucleoside re verse transcriptase inhibitor  or integrase strand t ransfer 
inhibitor  (NNRTI  or INSTI , not containing cobicistat)  who:  
 
 Are on ART for at least 2 years  
 Have virologic suppression defined as : (a) at least two HIV-1 RNA 
measurements < 50 copies/mL , one  of which was obtained within 336  
to 31 days , inclusive , prior to study entry and one obtained between 3 37 
and 730 days , inclusive , prior to entry, (b) no HIV-1 RNA values ≥ 50 
copies/mL within  336 days , inclusive , prior to study entry , and ( c) not 
more than one HIV -1 viral load equal to or greater than 50 and less than 
or equal to 200 copies/mL  from a result obtained between 3 37 and 730 
days, inclusive, prior to study entry  (and no HIV -1 viral load above 200 
copies/m L) 
 Have a plasma HIV -1 quantitative RNA with a lower limit of 
quantification  < 50 copies/mL (e.g., < 40 copies/mL) obtained  ≤ 30 
days prior to study entry  
 Have CD4+ T cell count >  350 cells/mm3 within 30 days pri or to study 
entry  
 Have no other medical conditions, or concomitant medications, 
prohibiting the use of a janus activating kinase -signal transducer and 
activator of transcription (Jak -STAT ) inhibitor    
 
STRATIFICATION  To ensure balance by treatment arm for EFV, participant s will be stratified 
at randomization  based on their EFV status (i.e., whether they are on an 
EFV-containing  regimen).  
 
REGIMEN  TDF/FTC  or ABC/ 3TC + (NNRTI or INSTI , not containing cobicistat ), with 
one of the following:  
 12 A5336  
FINAL  Version 2.0 
  05/21/15 
 
ARM A:  Treatment with r uxolitinib  10 mg orally twice daily  for 5 weeks.  
 
ARM B:  No study treatment.  
 13 A5336  
  FINAL  Version 2.0 
 SCHEMA (Cont’d)  05/21/15 
Arm A 
Study Week  RUX+AR T (ART not provided by 
study)  
   0              1                                      4               5                                                                                                                       12                
 Follow -Up (only ART ; ART not provid ed by study ) 
Arm B No Study Treatment; only AR T (ART not provided by study)  PK Collection  
 
 
Weeundetecta
ble PK Collection  
 
 
Weeundetecta
ble 
Study Week     0                                                                                                                                                                                                12                
  
 
Weeundetecta
ble  
 
Weeundetecta
ble HIV+ on ART  
Suppressed VL  2:1 
 
 
Wee
unde
tecta
ble 
 14 A5336  
FINAL  Version 2.0 
  05/21/15 
 
1.0 HYPOTHESE S AND STUDY OBJECTIVES  
 
1.1 Hypothes es 
 
1.1.1  The use of ruxolitinib for 5  weeks with antiretroviral therapy ( ART) consisting of: 
tenof ovir/emtricitabine ( TDF/ FTC) or abacavir /lamivudine ( ABC/ 3TC) + a 
nonnucleoside rev erse transcriptase inhibitor  or integrase strand transfer inhibitor  
(NNR TI or INSTI ) will be safe for vi rologically suppressed  participant s. 
 
1.1.2  The use of ruxolitinib f or 5 weeks with ART will be tolerable for virologically 
suppressed participant s.  
 
1.1.3  The use of ruxolitinib for 5 weeks with ART for virologically suppressed 
participant s will reduce systemic immune activation and inflammation.   
 
1.2 Primary Objective s 
 
1.2.1  To evaluate the safety of ruxolitinib in ART-treated HIV -1 infected virologically  
suppressed participant s during 5 weeks of treatment.  
 
1.2.2  To evaluate the tolerability of ruxolitinib in ART -treated HIV -1 infected 
virologically suppressed participant s during 5  weeks of treatment.  
 
1.2.3  To compare changes in interleukin -6 (IL-6) levels between baseline  and week 5  
in ART-treated HIV -1 virologically suppressed participant s who are randomized 
to ruxolitinib and those randomized to receive no study treatment . 
 
1.3 Second ary Objectives  
 
1.3.1  To evaluate the safety of ruxolitinib in ART -treated HIV -1 infected virologically 
suppressed participant s during all on-study visits  through week 12. 
 
1.3.2  To compare changes in IL -6 levels between baseline and week 12 in ART -
treated  HIV-1 virologically suppressed participant s who are randomized to 
ruxolitinib to changes in those participant s randomized to receive no study 
treatment.  
 
1.3.3  To assess whether the use of ru xolitinib will decrease levels of other measures of 
inflammatio n and immune activation  including  sCD14, tumor necrosis factor 
alpha ( TNF-α), IL-1α, IL-1β, IL-18, macrophage colony stimulating factor (m CSF), 
neopterin, HLA -DR, CD38, and both the distribution of monocyte subsets 
(defined by expression of CD14 + and CD16 +) and phenotypic indices of their 
activation during 5 weeks of treatment  and at week 12 . 
 
1.3.4 To examine whether the use of ruxolitinib is associated with changes in HIV -1 
plasma viral load levels (by a commercial clinical assay and single -copy assay) 
and CD4+ T cell counts in HIV -1 infected participant s at baseline compared t o 
12 weeks after initiation of treatment  for those receiving 5 weeks of ruxolitinib 
versus those receiving no study treatment .  
 15 A5336  
FINAL  Version 2.0 
  05/21/15 
 
1.3.5 To assess  changes from baseline in the HIV -1 reservoir , specifically plasma HIV -
1 RNA by single copy assay  (as above) , cellular HIV-1 RNA and total DNA , 2 
long-terminal repeat sequences [LTRs], and integrated DNA.  
 
1.3.6 To evaluate drug -drug interactions between ruxolitinib and antiretrovirals ( ARVs ) 
and to characterize the association between ruxolitinib pharma cokinetic (PK ) 
parameters  and changes from baseline in inflammatory biomarkers in 
participant s on the ruxolitinib treatment arm.  
 
1.3.7  To evaluate whether the use of ruxolitinib is associated with more frequent 
reactivation of human herpes  viruses (ie, cytomegaloviru s [CMV], Epstein 
Barr virus [EBV], herpes simplex viruses [HSV], human herpes viruses 
[HHV] 6, 7 , and 8) as measured in longitudinally collected oral swabs.  
 
1.4 Exploratory Objective  
 
To derive and evaluate a summary measure of immune activation and inflammation  
and how changes in this measure differ between the study treatment arm and the no 
treatment arm. 
 
 
2.0 INTRODUCTION  
 
2.1 Background  
 
Although ART presents a viable and well -established strategy for treating individuals 
living with HIV -1, a limitati on of current ART is the inability to completely reduce systemic 
inflammation  to that seen in age -matched controls in the general population . This 
inflammation has several consequences for individuals on ART including: (1) 
establishment o f a systemic pro -HIV-1 milieu resulting in an increase in  HIV-1 target 
cells, and possibly thereby maintaining HIV-1 viral reservoirs and allowing  infection  to 
persist  in various microenvironments; (2) less robust immunologic reconstitution  [1]; and 
(3) increased end -organ damage.  
 
Primary myelofibrosis is a myeloproliferative disease whereby the bone marrow is 
replaced with collagen fibrosis. This fibrosis occurs due to stromal cell overproduction of 
collagen stimulated by abnormal megakaryocytes. In response to the subseq uent 
pancytopenia, hematopoietic cells migrate out of the bone marrow resulting in 
extramedullary hematopoiesis and hepatosplenomegaly. A majority of patients with 
primary myelofibrosis have a somatic mutation in the gene encoding the cytoplasmic 
tyrosine kinase, Jak1/2, resulting in activation of Jak 1/2 signaling. Activation of the janus 
activating kinase and signal transducer and activator o f transcription ( Jak-STAT ) 
pathway leads to production of cytokines that cause the abnormal megakaryocytes to 
prolif erate. Ruxolitinib, a commerci ally available, US Food and Drug Administration 
(FDA)-approved Jak 2 inhibitor, disrupts this pathway. Many of the cytokines produced 
from Jak -STAT signaling are also cent ral to the pathogenesis of HIV. It is from this 
observat ion that ruxolitinib was first considered as a potential therapeutic option for HIV -
1 disease.  
 
 16 A5336  
FINAL  Version 2.0 
  05/21/15 
 
Ruxolitinib possesses unique qualities  distinct from those  of traditional ART, including 1) 
nanomolar  in vivo  inhibition of TNF -α, IL-6, and other pro -HIV infla mmatory cytokines , 
which have been associated with increased risk of morbidity and mortality in ART -
suppressed HIV -1 individuals  [2, 3], 2) sub -micromolar (0.1 µM) inhibition of  IL-2, IL-6, 
IL-7, IL-15, or  interfer on (IFN)-α induced activation of the Jak-STAT pathway in primary  
CD4+ T cell lymphocy tes, 3) sub -micromolar inhibition  of HIV -1/2 replication in primary 
human lymphocytes and macrophages, 4) down -regulation of HIV -1 induced activation 
in primary human lymphocytes,  and 5) direct inhibition of the Jak -STAT pathway, which 
is activated early in HIV -1 infection [4].  
 
These attributes of ruxolitinib could address many of the limitations of existing ART and 
provide a novel mechan ism to  1) reduce  reservoir seeding and homeostatic proliferation, 
which is driven by IL -7 and IL -15 orchestrated proliferation of stem -cell memory T cells 
(TSCM) and other latent T cell subsets;  2) reduce systemic inflammation by inhibition of 
IL-6 and oth er pro -HIV/pro -inflammatory cytokines, which would otherwise serve to 
promote pro -HIV-1 events including  (a) priming of uninfected cells for infection, (b) 
recruitment of uninfected cells to the site of infection, (c) reservoir maintenance  [5, 6], 
and to accelerate disease progression (including AIDS and serious non -AIDS events [ 7, 
8]; 3) reduce CD14 +/CD1 6+ monocytes and CD163 macrophages,  which can reduce 
trafficking of these activated, infected monocytes to the brain/ central nervous system 
(CNS ) where the y would otherwise either differentiate into macrophage -like cells 
containing HIV -1 or transfer infection to perivascular macrophages within the CNS  (this 
may also lead to a reduction in cardiovascular events via similar processes  [8, 9]), and 
4) confer ant i-HIV-1/2 potency across primary human lymphocytes and macrophages. 
Point 4 addresses persistent infection in macrophage -derived viral sanctuaries, which is 
not adequately controlled by current ART due to suboptimal intracellular concentration of 
ART in th ese cells  [10]. Additionally, as macrophages are long -lived cells that harbor 
virus, efficient inhibition of viral replication in these cells , and down -regulation of HIV -1 
induced activation (CD163) in these cells  by a mechanism distinct from direct inhibi tion 
of the viral replication cycle may provide a foundation to control inflammation -driven 
events including increased replication due to pro -inflammatory cytokines, induction of 
reactivation of virus from these cells, priming of uninfected macrophag es by 
inflammation induced m CSF, cerebrospinal fluid  production (which promotes viral 
replication), and trafficking of infected myeloid l ineage cells to the brain  (driven by HIV-1 
orchestrated activation of macrophages, w hich is marked by elevated CD163  levels) . 
Together  the potential ability of ruxolitinib to address these unmet needs could (a) 
contribute to control of persistent infection, (b) limit reservoirs  maintenance,  and (c) 
prevent ongoing infection across and within tissue compartments. Although adverse  
effects (AEs) exist, administration of ruxolitinib to patients with CD4 + T cell counts ≥ 350 
cells/mm3, platelet cou nts >  200,000/mm3, absolute neutrophil count (ANC) ≥  750/mm3, 
and hemoglobin ≥  12 g/dL with close monitoring for AEs  should not present a ny greater 
risk to safety compared to  HIV-1 infected healthy participant s on ART . 
 
The HIV -1 reservoir is comprised of latently infected cells, predominantly central memory 
and transitional memory CD 4+ T cell lymphocytes  [11], that contain integrated HIV -1 
DNA. Integrated HIV -1 DNA can remain latent or be actively transcribed; the effect of 
ruxolitinib on this equilibrium is unknown. To assess the effects of ruxolitinib on the HIV -
1 reservoir, markers of HIV -1 production (plasma and cellular HIV-1 RNA levels,  2-LTR 
circles) and persistence (total and integrated HIV -1 DNA) can be measured and followed 
longitudinally. HIV -1 2-LTR circles are dead -end, non -integrated DNA species that are 
 17 A5336  
FINAL  Version 2.0 
  05/21/15 
 
formed when HIV -1 infects a cell but the linear HIV -1 DNA fails to integrate  into the 
human genome. 2 -LTR circles can remain detectable for at least 10 -12 years during 
suppressive ART [12], and it remains unclear whether they are a marker of ongoing HIV -
1 replication or a byproduct of long -lived episomes maintained by latently -infected cell 
division.  
 
This study relies on the well -established anti -inflammatory profile of ruxolitinib in patients 
treated for primary myelofibrosis as a foundation to probe the effect of reducing 
inflammation on pro -HIV events described above in patient s that are virologically 
controlled on ART , so that the role of inflammation in HIV -1 infection can be more clearly 
defined. Should ruxolitinib efficiently inhibit inflammation  in the HIV -1 suppressed 
participant  on ART , it may be feasible that individuals  with well -controlled viremia 
receiving ART could undergo ther apy interruption to determine whether  viral rebound 
occurred post -ruxolitinib administration, either in the abse nce or presence of ruxolitinib. 
These data would ultimately define whether selecti ve, systemic inhibition of pro -
inflammatory/pro -HIV cytokines could  result in partial or total inhibition of viral rebound, 
or a functional cure. The study  is designed to address the inflammation -driven facets of 
ART-suppressed HIV -1 infection , and to expl ore a novel therapeutic strategy that 
reduces cellular activation and sy stemic inflammation, targets Jak -STAT signaling 
across lymphocytes and macrophages, and ensures viable delivery across the blood -
brain barrier ( BBB) to eliminate the HIV -1 reservoir of  the CNS.  
 
2.2 Rationale  
 
HIV-1 continues to be a global health crisis with more than 34 million people living with 
HIV-1 worldwide (UNAIDS/WHO). Despite the success of comb ination ART  in 
suppressing viral replication, HIV -1 continues to persist. Although several mechanisms 
likely contribute to persistence during ART, the stable integration of HIV -1 DNA within 
resting CD4 + T cells and perhaps cells of the monocyte/macrophage lineage is generally 
assumed to be the most important mechanism  [13]. All approved  ART drugs target steps 
in actively replicating virus, rendering them ineffective for 1) eliminating latent virus, 2) 
preventing or reversing reactivation of latent virus, 3) preventing recruitment of 
uninfected cells to the site of infection, and 4) inhib iting pro -HIV/pro -inflammatory 
cytokine milieus that drive chronic infection, disease prog ression, and end -organ 
damage. To this end, in the era of ART, it has become apparent that inflammation will 
continue to result in end -organ damage and eradication of  HIV-1 cannot occur without 
elimination of the latent viral reservoir . For these reasons, novel therapies are needed.   
 
Role of Jak -STAT Pathways in HIV -1 Infection   
The transcriptional status of HIV -1 is tightly coupled to the acti vation state of its hos t cell. 
The phosphorylation state of Jak -STAT pathways is  known to influence HIV -1 infection 
in various target cells [14, 15]. HIV-1 orchestrated pro -inflammatory cytokines or 
envelope gp120 activates Jak  and STAT proteins  leading to expression of multiple 
receptors and/or cytokines and generalized immune dysfunction (including activation) in 
a variety of HIV -1 target cells, including primary human lymphocytes and macrophages 
[4, 8-9, 13 -19]. Cytokines that are upregulated and expressed in clude IL -6, TNF -α, and 
IFN-1α/β [20-23]. Inflammation, most notably associated with IL -6, can co ntribute to 
reseeding and maintenance  of the viral reservoir because IL -6 stimulates HIV -1 
replication by activating viral transcription in synergy with TNF -α and also by targeting a 
post-transcriptional step [ 24, 25]. 
 18 A5336  
FINAL  Version 2.0 
  05/21/15 
 
Blocking Jak -STAT signaling pathways  could reverse or prevent HIV -induced activation 
of both macrophages and lymphocytes, thereby reducing HIV -orchestrated systemic 
immune activation and suppressing chronic inflammation. Consequently, HIV -1 
production from latently infected cells and HIV -1 infection of new target cells may 
decrease. Inhibition of these pathways may also reduce trafficking of virus and infected 
cells across the BBB, preventing CNS  persistence and HIV -associated neurocognitive 
disease. Since HIV -1 infection of macrophages causes  alterations in the cell cycle [26], 
chemotaxis [27], increased levels of TNF -α and other TH2 -type cytokines [28], 
phagocytosis [29, 30], and antigen presentation [31], inhibition of Jak -STAT pathways 
might have profound beneficial effects on these cells.  
 
Consequently, we anticipate that by blocking Jak -STAT si gnaling, the CD4 + T cell count 
could also increase ow ing to two primary mechanisms: 1) a reduction in HIV -1 
replic ation -dependent cell death and 2) a reduction in bystander apoptosis -induced cell 
death independent of HIV -1 replication. The first mechanism relies upon the theory that 
there is ongoing HIV -1 replication in sanctuary sites despite suppressive ART [ 32-34]. In 
this setting, a reduction in pro -inflammatory cytokines could  result in fewer target cells 
trafficking to sites of infection, decreased ex pression of chemokine receptor type 5 
(CCR5 ) and other cellular activation markers that would otherwise make uninfected cells 
more permissive to HIV -1 infection, and fewer virus particles would be produced per 
HIV-1 infected cell.  
 
Monocytes/Macrophages as  a Reservoir for HIV -1 
Cells of the monocyte/ macrophage lineage have, as of yet, a poorly defined role in HIV -1 
persistence during long -term ART. Several studies have shown a corr elation between 
activated, CD14 +/CD1 6+ monocytes and HIV -1-associated neuroco gnitive impairment, 
immune activation, higher viral loads , and disease progression [ 35-38]. In untreated HIV -
1 and possibly treated HIV -1 disease, carriage of HIV -1 across the BBB by infected 
monocytes , activated macrophages,  and lymphocytes establishes a persistent infection 
primarily in perivascular macrophages and microglia as viral reservoirs in the immune -
privileged CNS (the “Trojan horse” hypothesis) [22, 36, 39]. In contrast to HIV -1 infected 
CD4+ T cells, in fection in brain macrophages and microglia leads to an extended life 
span and increased survival in the presence of apoptotic stresses, while concomitantly 
orchestrating a pro -inflammatory cytokine milieu that drives viral replication in already 
infected c ells, primes uninfected cells for infection, and results in produc tion of reactive 
oxygen species  and other factors that drive HIV -associated neurocognitive impairments 
[20, 40-44]. In addition, viral proteins expr essed early in the viral replication cycle (such 
as Nef, Tat, and virion -associated Vpr) play a role in the formation of viral reservoirs in 
macrophages by activating transcription and interfering with apoptotic machinery [19].  
 
The BBB also consists of  a number of unique elements that prevent passage of many 
drugs into the brain (as also seen in lymphoid tissue). Several drug physical properties 
influence the penetration of drugs through the BBB, including molecul ar weight, protein 
binding, lipophilicity, and the action of passive and adenosine triphosphate  (ATP)-
dependent influx and efflux pumps [45]. Viral populations in the CNS can diverge fro m 
those of plasma due to the resulting differences in tissue drug exposures. Furthermore, 
the dynamic interaction between signaling pathways that promote virus replication, 
active/infiltrating macrophages, cytokines/chemokines, and secreted neurotoxic 
products, may interfere with the overall homeostatic regulation required to maintain 
normal quiescent brain function.  The ov erall mechanism of action of Jak  inhibitors and 
 19 A5336  
FINAL  Version 2.0 
  05/21/15 
 
their role in inhibiting pro -HIV-1 events that are n ot addressed by current highly acti ve 
ART are depicted below in Figure 1.   
 
 
Figure 1. The Jak -STAT pathway is activated by either HIV -orchestrated pro -inflammatory 
cytokines or HIV -1 gp120 engaging the host cel l (upper left panel). Upon activation, multiple pro -
HIV-1 events transpire, in cluding 1) increased production of virus in already infected cells;  2) 
priming of  uninfected cells for infection;  3) recruitment of uninfected cells to the site of infection, 
therefore exposing them to infection  and priming them for infection;  4) activatio n of monocytes 
and macrophages, which promotes trafficking of these infected ce lls across and to the CNS/brain;  
and 5) microbial translocation in the gut (boxes above). Use of Jak inhibitors  prevents activation 

 20 A5336  
FINAL  Version 2.0 
  05/21/15 
 
of the Jak -STAT pathway, mitigating these pro -HIV-1 events (upper right panel) [ 46, 47]. 
 
Table 1:  The Proposed Impact of Ruxolitinib on Various Biomarkers Relevant to HIV -1 
Pathogenesis, Immunologic Recovery , and the Reservoir  
 
Marker s  Role in HIV -1 infection in the 
absence of ruxolitinib  
CD14+/CD 16+  monocytes  Trafficking of infected monocytes to 
the CNS and across the BBB  
CD163  A: Trafficking of infected 
macrophages to the CNS and across 
the BBB  
B: Recruitment of macrophages to 
privileged sites of low level 
replication  (gut, lymph nodes, 
others)   
IL-6, IL-1, TNF -alpha, GM -CSF A: Prime uninfected cells for 
infection  
B: Produce more virus per infected 
cell 
C: Drive gut microbial translocation  
D: Impact end-organ disease such 
as cardiovascular, neurocognitive 
and malignancies  
E: Potential impact on  collagen 
deposition in the bone marrow but 
this effect was  previously implicated 
in individuals with myelofibrosis  
IL-7, IL-15 Drivers of homeostatic proliferation 
of latently infected memory 
lymphocytes  
pSTATs binding to HIV -1 LTR  Promotes  HIV-specifi c gene 
transcription  
 
Ruxolitinib   
The commercially available  Jak 1/2 inhibitor , ruxolitinib ( (3R)-3-cyclo -pentyl -3-[4-(7H-
pyrrolo  [2, 3-d]pyrimidin -4-yl)pyrazol -1-yl]propanenitrile; Jakafi , Incyte Corporation  and 
Novartis), acts by interfering with the binding of ATP to  Jaks. Ruxolitinib was approved 
by the FDA  for treatment of persons with intermediate and high -risk myelofibrosis [48] 
and polycythemia vera . Other clinical trials are currently underway to determine its 
efficacy and safety for the treatment of rheumatoid arthritis  (RA), autoimmune  psoriasis , 
and various malignancies.  
 
In vitro studies performed at Emory University demonstrate antiviral potency of ruxolitinib 
in HIV -infected monocyte -derived macrophages (MDM) and lymphocytes grown in 20% 
serum. The EC 50/90 in macrophages was in the  range of 0.09/1.3 to 0.3/4.8 µM with and 
 21 A5336  
FINAL  Version 2.0 
  05/21/15 
 
IC50 (cellu lar toxicity) of 13.4 to >100. The EC 50/90 in lymphocytes ranged from 0.02 - 4.7 
µM with no effect on viability up to 50 µM  [49]. Furthermore, ruxolitinib has a short 
plasma t 1/2 (~3 hr), so that the dur ation of exposure to ruxolitinib is considerably shorter 
than in vitro exposure (5 days). Maximal plasma concentrations in humans (C max) are 
between 3.6 -10.0 µM and persist for < 30 min [50, 51] demonstrating a wid e therapeutic 
window of safety.  
 
Ruxolitinib is a nanomolar in vivo inhibitor of TNF -α, IL-6, and other pro -HIV 
inflammatory cytokines (see Figure 2, based on p hase I/II and III clinical studies) [2, 3], 
and i s a direct inhibitor of the Jak -STAT pathway s activated early in HIV -1 infection [4]. 
Data provided by Incyte Corporation  on participant s treated with ruxolitinib for 
myelofibrosis (Study INCB 18 424-256) demonstrated t hat inhibition of pro -inflammatory 
and activation markers were observed within 2 weeks of administration of ruxolitinib 25 
mg twice a day ( BID), and in many cases were observed as early as 3 days post 
administration (Figure 4). Overall, ruxolitinib  is a promising drug  for further testing  as a 
modulator of inflammation  due to its well -documented safety profile and nanomolar ant i-
inflammatory action in humans  together with its sub -micromolar antiviral activity against 
HIV-1 in culture [50, 52].  
 
 
Figure 2 (adapted from [ 2, 3]). Changes in selected cytokines and C -reactive protein, an acute 
phase reactant and a marker for inflammation, show in patients with > 50% decrease those with <  
50% decrease, and those with no c hange or an increase in the composite symptom score after 6 
cycles of treatment as compared with baseline, where y -axis is reported as “points” which is a 
change cytokine level versus baseline (A), or median change in IL -6 levels versus baseline 
(percent) (B).   
 
Safety of Ruxolitinib  
Over 9,800 individuals have or are currently taking ruxolitinib, as reported by Incyte  
Corporation . Post -marketing surveillance for safety of this drug has continued since it 
was approved for myelofibrosis by the FDA in Novemb er 2011, with no recommended 
change s by the FDA. Additionally, Dr. Srdan Verstovsek, the first author of the clinical 
trials performed with ruxolitinib for myelofibrosis, stated that their longitudinal study has 
not identified any new toxicities [50]. In his review, all published reports have shown 
satisfactory safety data on 1,400 participant s with no new toxicities [53]. 
 
In the initial dose -finding study of ruxolitinib in myelofibrosis  (Study INCB 18 424-251), 
the most common AEs  observed included hematologic (thrombocytopenia and anemia) 
and non -hematologic AEs  which were infrequent (br uising, dizziness, and headache) 
after a median of 14.7 months on therapy [2]. There were few Grade 3 or 4 events when 
 22 A5336  
FINAL  Version 2.0 
  05/21/15 
 
using FDA -approved doses (15 mg BID or  20 mg BID depending on the platelet count 
and adjusted as needed for efficacy o r toxicity). Of the 153 participant s in the study, 
serious adverse  events (SAEs) occurred in 59 participant s, of whom on ly 12 had SAEs  
that were considered to be possibly relat ed to treatment. The hematologic events varied 
by the dosing regimen (Table 2a). Diarrhea, fever , and urinary tract infections were 
described in 5.9%, 2% , and 2 .6%, respectively , for all grades  with only 0.7% having a 
Grade 3 or 4 fever. Individuals with H IV-1 were excluded from these studies.  
 
In the p hase III COMFORT -1 study in individuals with myelofibrosis (FDA dosing as 
above), there was a survival advantage when compared to placebo with 13 deaths in the 
ruxolitinib group (8.4% , N=155) and 24 deaths in  the placebo group (15.6% , N=154) 
during a median follow -up period of 51 weeks [3]. Among the deaths, there was no 
detectable increase risk of serious infections; pneumonia occurred in two  participant s 
who received  ruxolitinib and one  who received p lacebo, and sepsis occurred in two  
participant s from each arm. Although two  participant s developed  acute myelogenous  
leukemia  (AML) after receiving ruxolitinib, they were at increased risk for this disease 
prior to receiv ing the study drug. Grade 3 or 4 thrombocytopenia occurred in 12.9% of 
the ruxolitinib arm an d 1.3% in the placebo arm with G rade 3 episodes of bleeding in 
2.6% of participant s in the ruxolitinib arm and 2.0% in the placebo arm; 1.3% of 
participant s in eac h arm ha d Grade 4 episodes of bleeding. There was one G rade 3 
event of bruising in the ruxolitinib arm. Thrombo cytopenia rarely recurred at a G rade 3 or 
4 level aft er appropriate dose reduction  and was not associated with an increase in 
bleeding events, al though bruising was more common in the ruxolitinib group. Grade 3 
or 4 anemia peaked at weeks 8 to 12 and then subsequently declined to levels similar to 
those in placebo -treated participant s.  
 
A longer term evaluation of  107 participant s enrolled in the open label, non -randomized 
phase I -II study of ruxolitinib  (INCB 18 424-251) showed that  49 (46%) discontinued 
ruxolitinib by 3 years (24 by year 1, 36 by year 2, and 46 by year 3). Of those who  
discontinued treatment, only 3 (2.8%) did so for unacceptable toxicity. The others 
discontinued for progressive disease (12), withdrawal of consent (7), physician decision 
to discontinue (5), intercurrent illness (3), death (13), or other reasons (6). None of the 
deaths were considered by the investigator s as related  to ruxolitinib , see T able 2 b. [52]. 
A cohort description in 120 Asian participant s treated for myelofibrosis with ruxolitinib 
was published online in late 2014 [5 4]. The authors concluded that, “Adverse events 
were consistent with those seen in the COMFORT studies.” The principal AEs were 
anemia, thrombocytopenia and diarrhea. Of 7 deaths that occurred in the cohort, one 
death due to sepsis and one due to hepatorenal syndrome were suspected by the 
investigator to b e related to ruxolitinib treatment . 
 
 
 
 
 
 
 
 
 
 
 
 23 A5336  
FINAL  Version 2.0 
  05/21/15 
 
Table 2. (a) Hematologic AEs [2] (*red box ) indicates dose similar to that propose d for 
this study, (b) Rate and Reasons for Discontinuation in S tudy INCB18424 -251 [ 52]. 
 
a. Hematologic Adverse Events  
Variable  10 mg 
Twice  
Daily  15 mg 
Twice 
Daily  
 25 mg 
Twice 
Daily  
 50 mg 
Twice 
Daily  
 25 mg 
Once  
 Daily  
 50 mg 
Once  
 Daily  
 100 
mg 
Once  
 Daily  
 200 mg 
Once  
 Daily  
  
Total  
Thrombocytopenia – no./total no. (%)*  
 
Grade 3  3/29  
(10) 1/35  
(3) 11/47 
(23) 3/5  
(60) 0/6  
(0) 6/22  
(27) 2/6  
(33) 0 26/153 
(17) 
Grade 4  0 0 3/47  
(6) 1/5  
(20) 0 2/22  
(9) 0 1/3  (33)  4/153  
(3) 
New anemia Ŧ, 
participant s 
who were 
transfusion 
independent   
3/19 
(16)  
2/24  
(8)  
8/30 
(27)  
0/2  
(0)  
1/4  
(25)  
5/15 
(33)  
1/4  
(25)  
3/3 
(100)   
23/101 
(23) 
* Values for platelet count abnormalities were graded according to the Common Terminology Criteria for 
Adverse Events (CTCAE), version 3.0 (Grade 3 = 25 x 109/liter to < 50 x 109/liter; Grade 4 = < 25 x 
109/liter.   
Ŧ Anemia was defined as a decrease in the hemoglobin level of more than 20 g per liter to a Grade 3 or 4 
level (as defined according to the CTCA E, version 3.0) in patients who were not transfusion dependent.   
 
b. Rate and reasons for discontinu ation in study INCB18424 -251, An Open -Label, 
Nonrandomized Phase I -II Study of R uxolitinib  
                                                                  MDACC                         Mayo Clinic Rochester  
Participant s Enrolled, N  107 51 
Participant s remaining on 
study, N (%)  58 (54)  5 (10)  
Participant s who discontinued, 
N, (%)  49 (46)  46 (90)  
     Discontinued by 1 y., %  24 51 Ŧ 
     Discontinued by 2 y., %  36 72 Ŧ 
     Discontinued by 3 y., %  46 Ŧ Ŧ 89 Ŧ 
Primary reason for discontinuation,* N, (%)  
     Death  13 (12.1)  4 (7.8)  
     Progressive disease  12 (11.2)  10 (19.6)  
     Participant  withdrawal of  
     Consent  7 (6.5)  15 (29.4)  
     Physician decision to       
     Discontinue  5 (4.7)  12 (23.5)  
     Intercurrent illness  3 (2.8)  0 
     Unacceptable toxicity  3 (2.8)  1 (2.0)  
     Other  6 (5.6)  4 (7.8)  
Data provided by Incyte Corporation  upon MD Anderson Cancer Center  request.  
 24 A5336  
FINAL  Version 2.0 
  05/21/15 
 
* As categorized by defined headings on case report forms  (CRFs) filled out by the investigator.  
Ŧ Discontinuation rates  as published in Tefferi et al in 2011[ 55].  
Ŧ Ŧ NOTE : not all ongoing participant s have reached year 3; by Kaplan -Meier analysis, the  
     discontinuation ratio at year 3 was 53 %.  
 
Additional safety data on ruxolitinib from studie s conducted for other indications are 
available  online at “ClinicalTrials.gov ”; however, causality of side effects listed was not 
determined in these reports. As an example, the “Study to Determine the Safety and 
Efficacy of Ruxolitinib (INCB018424) in Participant s With Polycythemia Vera (PV) or 
Essential Thrombocythemia (ET)” had 13.7% (10/73) of participant s with SAEs  that 
varied depending on the dose (10 mg BID, 25 mg BID , and 50 mg QD ) and underlying 
disease (PV or ET) , and the SAE included one report e ach of pneumonia, 
thrombocytopenia, anemia, renal cancer, renal failure, congestive cardiac failure, atrial 
flutter, headache, variceal bleeding, gastrointestinal bleeding, cholecystitis and 
bronchitis. In a second metastatic prostate cancer study, out of the 22 participant s who 
received ruxolitinib and experienced an SAE, two had anemia , and there was one report 
each of an overdose, pathologic fracture, cardiac arrest, sepsis, gastrointestinal 
bleeding, prostate cancer metas tasis, metastatic pain , hydronep hrosis , and renal failure. 
In a third mult iple myeloma study, out of 20 participant s who received either ruxolitinib 
(N=13) or ru xolitinib plus dexamethasone (N= 7), there were three SAE reports of 
pneumonia, two reports each of gastrointestinal bleeding an d disease progression, and 
one report each of anemia, congestive cardiac failure, pericardial effusion, pyrexia, 
fatigue, pain, pneumococcal sepsis, urinary tract infection, overdose, hyperglycemia, 
lung cancer, seizure, pulmonary embolism , and hematoma. T he incidence of SAE was 
significantly higher in the ruxolitinib plus dexamethasone group versus ruxolitinib group. 
Progressive multifocal leukoencephalopathy (PML)  [56], reactivation of latent 
tuberculosis  (pulmonary [ 57, 58] and disseminated [ 59, 60]), hepatitis B infection [ 61, 
62], herpersvirus infections [ 63], Pneumocystis jiroveci pneumonia [ 64], toxoplasmosis 
retinitis [ 65], and Cryptococcus neoformans  pneumonia [ 66] have been reported on 
participant s who received ruxolitinib treatment for myelof ibrosis.  
 
Incyte Corporation  provided unpublished data presented at both the American College of 
Rheumatology (ACR) meeting as well as unpublished data obtained internally, 
demonstrating that 10 mg ruxolitinib BID has equivalent efficacy for cytokine reduc tion, 
but the ave rage change in hemoglobin and platelet count is negligible. These data 
demonstrate that 10 mg BID is sufficient to inhibit production of pro -inflammatory and 
activation markers while concomitantly mitigating any potential detrimental side effects 
that w ere observed at higher dosages. Therefore , for this study the 10 mg BID dose has 
been selected for the treatment arm in order to minimize treatment -related AEs  while 
maximizing efficacy.  
 
Dose Effects on Biomarkers  
Data  on cytokine changes in  participant s treated with lower doses of ruxolitinib for 
myelo fibrosis were provided  by Incyt e Corporation . Additionally, data on cytokine 
changes in participant s treated with lower doses of ruxo litinib for RA  have been 
obtained from an oral presentation at the 2008 American College of Rheumatology 
Annual Scientific Confer ence. Both of these data sources demonstrate reductions in 
levels of various biomarkers (see heatmap below , Figure 3 ), as well as RA  and 
myelofibrosis symptom sc ores with doses as low as  5 mg BID.    
 
 25 A5336  
FINAL  Version 2.0 
  05/21/15 
 
Aggregate data have bee n provided by Incyte Corporation  relative to the dose of 10 or 
15 mg BID ruxolitinib  in Study INCB  18424 -356, “Study of Efficacy and Safety in 
Polycythemia Vera Participant s Who Are Resistant to or Intolerant of Hydroxy urea: JAK 
Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE 
Trial)” . Many participant s in the  study did not demonstrate levels of IL -6 above the 
lower limit of detection (LLD) of 6 pg/mL at baseline. Therefore, at endpoint 
measurement, it was not possible to determine whether their IL -6 levels had decreased 
(Figure  5 below ). Considering only those participant s with elevated levels of IL -6 at 
baseline, four of six participant s demonstrated significant decreases in IL -6 levels 
(Figure 6  below). The participant s with a low baseline IL -6 level could have had a 
decline in IL -6 while on ruxolitinib but those changes would not be detected by the assay 
used. A more sensitive assay for IL -6 will be employed in A5336, with a LLD of 0.2 lo g10 
pg/mL (SD=0.25 log 10 pg/mL ). This will allow us to measure an effect for any 
participant s with a base line IL -6 above approximately 0.5 pg/mL.  
 
There are published data in myelofibrosis showing that symptomatic improvement for 
symptoms thought to be ca used by elevated inflammatory cytokines, including n ight 
sweats, pruritu s and bone p ain are equally improved at doses of 10 mg BID as at highe r 
doses up to 25 mg BID. There is a clear drop off in symptomatic benefit when the dose 
is lower than 10 mg BID (g iven as 5 mg BID) , but even at that level there is improvement 
compared to placebo  [67]. Reductions in phosphorylated -STATs and Jak s at 10 mg BID 
are also observed in myelof ibrosis and RA  studies, each of which are surrogate markers 
for down regulation of IL-6 levels.   
 
Figure 3. Ruxolitinib decreases levels of IL -6 biomarker  
 
 26 A5336  
FINAL  Version 2.0 
  05/21/15 
 
 
Figure 4. Changes in inflammatory markers demo nstrate predominant effect at 4 weeks (28 days) 
for 21 participant s with myelofibrosis receiving 25 mg BID (Study INCB 18424 -256) 
  
 
  
Figure 5. Participant s with and without elevated IL -6 at baseline  who receive d 10-15 mg BID for 
polycythemia vera and essential thrombocythemia (Study INCB18424 -356) 
  
 27 A5336  
FINAL  Version 2.0 
  05/21/15 
 
  
Figure 6:  Participant s with elevated IL -6 at bas eline who received 10 -15 mg BID for 
polycythemia vera and essential thrombocythemia (Study INCB18424 -356) 
 
Pharmacology of R uxolitinib  
The FDA-approved starting dose is 20 mg given orally (PO) BID  for participant s with a 
platelet count >  200,000/mm3, 15 mg PO BID  for participant s with a platelet count of 
100,000/mm3 to 200,000/mm3, and 5 mg PO BID  for participant s with a platelet count 
between 50,000/mm3 and 100,000/mm3. Data from Incyte Corporation  have  shown that 
ruxolitinib can be dosed at 10 mg BID  with roughl y equivalent myelofibrosis efficacy and 
significantly reduced AEs compared to higher doses.  Dose reductions and subsequent 
dose increases in clinical trials and in the clinical setting are quite common with ra pid 
resolution of AEs  (and improvement in clini cal indicators). Similarly, titrating dose to 
effect is both recommended and commonly pract iced as well. Therefore, the protocol 
team has  chosen to use a dose of 10 mg BID  (without dose escalations) for all 
participant s in this  study and will exclude parti cipant s with plate let counts ≤  
200,000/mm3.  
 
Ruxolitinib is a substrate of CYP3A4, but not an inhibitor of this enzyme (see package 
insert). It is recommended that w hen administering ruxolitinib with strong CYP3A4 
inhibitors, the total daily dose of ruxol itinib shoul d be reduced to 5 mg BID  (i.e., 
approximately 50% of the dose rounding up to the nearest dosage strength). No dose 
adjustment is necessary for mild or moder ate CYP3A4 inhibitors (see package insert). 
Raltegravir and other INSTI  are not substrat es for CYP3A4.  
 
Safety and Coadministration of EFV with Ruxolitinib  
Efavirenz is classified as a moderate CYP3A4 inducer  [68]. No dose adjustment is 
recommended when ruxolitinib is co administere d with a CYP3A4 inducer ( see package 
insert). However, plasma AUC values for ruxolitinib metabolites increased with 
  Upon removal of participant s who did not have elevated levels of IL -6 at start of 
study, an d consideration of only participant s with elevated IL -6 at baseline, it is 
clear that 10 -15 mg BID ruxolitinib reduces IL -6 levels by week 4  
 
 28 A5336  
FINAL  Version 2.0 
  05/21/15 
 
increasing severity of renal impairment.   
 
Metabolites of Ruxolitinib  
Metabolites of ruxolitinib act on the same  pharmacological receptors , however at lower 
potency (1/5 to 1/2 of the parent compound) and at relatively low concentrations. 
Therefore, when ruxolitinib is metabolized, the effect of the metabolite is between 20 -
50% of the original parent compound. Thus,  the contribution of toxicity resulting from an 
increase in drug metabolites would be mor e than compensated for by a net decrease in 
concentration of the parent drug.  The rates of  elimination half -life of ruxolitinib and its 
metabolites are rapid and similar  (approximately 3  – 5.8 hours ). Therefore, steady -state 
accumulation is not expected to  occur  (see more at:  
http://www.incyte.com/sites/default/files/Jakafi_PI.pdf?time=20141230135651 ). The 
dose sele cted for this study is 10 mg BID , which is the recommended reduced dose  and 
is below or equivalent to package insert guidelines when considering metabolites of 
ruxolitinib in the presence of EFV.   
 
The mass bala nce trial INCB 18424 -134 reported  that following a single 25 mg dose of 
ruxolitinib s olution (100 μCi 14C -ruxolitinib) parent drug was the predominant entity in 
circulation, representing 58% to 74% of the total radioactivity between 1 and 6 h post -
dose. Metabolite M18 was observed at 17% of the total, circulating, drug -related material 
based on AUC and the other observed ruxolitinib mono - and di -hydroxylated and ketone 
metabolites rep resented less than 10% (Figure 7). Eight of these metabolites (M7, M8, 
M9, M11, M14, M16, M18 , and M27) when added to parent drug, accounted for greater 
than 9 0% of the drug -related material in circulation (based on AUC). No metabolites 
were observed in human plasma after 12 h post -dose.  
 
 29 A5336  
FINAL  Version 2.0 
  05/21/15 
 
 
Figure 7 : Metabolites of r uxolitinib. In summary, M18 is the major metabolite with 17 %; sum of 8 
other metabolites ≤10%.  
 
Justification for Choice of IL -6 as a Primary Endpoint M arker   
IL-6 has been the most highly implicated biomarker for end -organ disease and mortality 
on ART. A number of inflammation -associated biomarkers have demonstra ted 
prognostic significance in well -treated HIV -1 infection. These include IL -6, D-dimers, 
sCD14, sCD163, anti -TNF-receptor,  CRP, monocyte phenotype, and T cell activation. 
Perhaps the most consistent  and well -validated biomarkers are  IL-6 and D -dimer. In the 
SMART study, IL -6 levels were m ost strongly associated with cardiovascular disease 
(CVD)  and mortality (odds ratio for 4th/1st quartile of 3.5 and 11.8 for CVD and mortality, 
respectively) [ 69, 70]. These results were confirmed in a large anal ysis of a ll treated 
participant s in the INSIGHT families (which included ESPIRIT and SILCAAT, n=3766), 
a single determination of IL -6 was associated with disease progression over the 
subsequent 5 to 8 years. The prognostic significance of IL -6 in treated HIV -1 disease 
was confirmed in a longitudinal analysis of participants  in ALLRT and a case -control 
study from participant s enrolled in SOCA/SCOPE [ 71, 72]. A number of other studies 
have confirmed that IL -6 is higher than expected in treated HIV -1 disease [ 73-75], and 
associated with poor prognosis [ 8, 76, 77]. The impact of IL -6 on prognosis is generally 
not attenuated after controlling for viral load, CD4+ T  cell count , and other factors. To our 
knowledge, there is no other biomarker which has been so consistently associated with 
disease progression in the context of treated HIV -1 disease. Furthermore, mutations in 
the IL -6 gene have been associated with increased IL -6 levels coincident with an  ruxolitinib  
 30 A5336  
FINAL  Version 2.0 
  05/21/15 
 
increase in CVD , placing IL -6 in the casual pathway, not just as a surr ogate marker of 
inflammation [7] but as an earlier predictor of disease progression [78]. 
 
In order to assess feasibility, we examined participant s who were analyzed as part of 
NWCS 329 , wherein participant s from seve ral ACTG trials were followed  for 
cardi ovascular and malignant endpoints. Cases and controls were selected based on 
these particular outcomes . Among the 171 controls with viral load < 50 copies/mL and 
CD4+ T cell > 350 cells/mm3 at 1 year after ART initiation, the following IL -6 quartiles 
were identified:  
 
Quartile 1 (25%):  IL-6 < 0.86 
Quartile 2 ( 26%):  IL-6 = 0.86 to 1.42  
Quartile 3 ( 20%):  IL-6 = 1.43 to 2.0  
Quartile 4 ( 29%)  IL-6 ≥ 2.1 
 
Based on these data, we believ e that a reasonable number of participant s will have 
levels of IL -6 within a r ange conducive for appreciating a reduction in the presence of 
ruxolitinib.  
 
Justification for the Choice of Assay to Measure C hanges in IL -6  
We have measured plasma levels of IL -6 using the R&D high sen sitivity assay. This is a 
solid-phase sandwich ELISA  that can be performed on serum or plasma. In this ass ay, 
the LLD  is usually around 0.16 pg/mL, and the assay range is 0.11 pg/mL -10 pg/mL. The 
manufacturer reports that there is <  0.5% cross -reactivity observed with molecules 
related to IL -6. Using thi s assay, it was reported [63] that among 60 participant s with 
virologic control and immune failure (CD4+ T  cell < 350/uL), 20 participant s with 
virologic control and immune success (CD4+ T  cell > 500/uL) and 21 healthy controls, 
none had IL -6 levels in plasma  lower than 0.46 pg/mL. Samples are obtained in EDTA 
and processed and cryopreserved within 6 hours of blood draw. Assays are performed 
on cryopreserved samples using manufacturer’s instructions and inter -assay consistency 
is evaluated by running an aliquo t of the same sample on each plate. Thus we are 
confident that our assay is sensitive enough to measure IL -6 levels in plasma in our 
study participant s.  
 
HIV-1 Persistence   
Recent in vitro data have  provided further insight into the potential role for rux olitinib to 
affect the HIV -1 reservoir.  
 
Overall, the potential mechanisms impacted by ruxolitinib include the following:  
 
1. Seeding of the HIV -1 reservoir: Recent  data (Figure 8) and others show that γ -C 
receptor cytokines (IL -2, IL-7, IL-15) which are triggered by chronic  T cell receptor  
(TCR) activation and bystander immune activation (bacterial translocation, alarmins) 
can upregulate HIV -1 transcription and production . This is  because  the sequence of 
the HIV -1 LTR includes STAT  binding sites [5, 79]. This ultimately results in 
increased numbers of infected cells, increased production of viral particles and an 
enhanced seeding of the H IV reservoir. Inhibition of Jak -STAT signaling pathways 
should decrease the number of HIV -1 infected cells and ultimately the HIV -1 
reservoir.  
 
 31 A5336  
FINAL  Version 2.0 
  05/21/15 
 
2. Maintenance of the HIV -1 reservoir: W e have shown that IL -7 (a γ -C receptor 
cytokine) maintains and expands the latent HIV -1 reservoir by triggering homeostatic 
proliferation [5]. Inhibition of homeostatic proliferation downstream of cytokines such 
as IL-7 and IL -15 should result in a decreased expansion/maintenance  of the latent 
HIV-1 reservoir.  
 
3. Inhibition of cytokine induced inflammation driven HIV -1 replication and T cell  
dysfunction/exhaustion: Several pro -inflammatory cytokines, which are upregu lated 
in HIV -1 infection, enhance HIV -1 replication as they can activate T cells  thereby 
increasing expression of CCR5 and trafficking of these cells to sites of infection ; they 
also inhibit T cell and innate immune function as these cytokines upregulate t ype I 
interferons (IL -7, IL-15) and  several negative regulators of T cell activation (PD -1, 
Lag-3) and their ligands (PDL -1, MHC II) in individuals with HIV -1. This should 
induce HIV -1 latency in cells expressing these molecular factors [5, 22, 79, 80]. 
 
4. Inhibition of Jak -STAT may prevent the induction of an HIV -1 latent pool by  
preventing expression of negative regulators on T cells and their ligands on innate 
immune cells. This could result in the restoration of innate and adaptive immune 
function, two critical steps in controlling or eliminating latently infected cells and a  
functional cure  [81]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  8. Inhibition of HIV -1 Replication by Ruxolitinib. Viral production as measured by p24 
ELISA  in primary CD4 + T cells isolated from a viremic donor stimulated for 3 (A) and 6 days 
(B) with CD3/28 in the presence of increasing concentration of ruxolitinib or DMSO (vehicle) 
only, reported in µM (x -axis).  
 
Infectious HIV -1 reservoir measurements us ing a quantitative virus outgrowth assay (Q -
VOA) may underestimate reservoir size [82] and require larger volume blood draws than 
are feasible in this study. We plan to use total and integrated HIV -1 DNA levels as 
markers of HIV -1 persistence and plasma HI V-1 RNA and peripheral blood mononuclear 
cells ( PBMC )-associated HIV-1 RNA and 2-LTR circles as markers of HIV production. 
Measurement of plasma virus load , cellular RNA  and 2 -LTR circles will examine two 
different components of HIV -1 replication: the amou nt of virion production that may occur 
during ruxolitinib therapy and the degree to which virions may infect cells and yet fail to 

 32 A5336  
FINAL  Version 2.0 
  05/21/15 
 
form proviruses. STAT -5-like sequences are present in the HIV -1 LTR and suggest a 
mechanism whereby ruxolit inib treatment may  modulate HIV -1 latency. 2 -LTR circle 
quantification will corroborate changes that may be observed in total HIV -1 DNA, relative 
to integrated HIV -1 DNA, during ruxolitinib therapy.  
 
Activation of Viral Co-infections  
Previous studies reported  reactivation o f herpes  viruses among participants  
receiving ruxolitinib for clinical indications; however, the use of other 
immunosuppressant therapies makes it impossible to assess the individual 
contribution of ruxolitinib [83, 84]. As part of this study we will deter mine whether 
the use of ruxolitinib is associated with more frequent reactivation of human HHV 
as measured in longitudinally collected oral swabs. Shedding of HHV DNA is 
frequently detected in saliva of healthy individuals and more frequently in HIV -
infect ed adults and persistent replication of HHV  (in particular CMV) was 
repeatedly associated with increased systemic inflammation and cellular 
activation [85, 86, 87]. As an alternative hypothesis, since persistent inflammation 
can also be a trigger for HHV r eactivation, reduction in inflammation after 
ruxolitinib administration might be associated with decrease in HHV repl ication .  
 
If treatment with ruxolitinib is associated with increased oral shedding of HHV, we 
will determine whether  the presence of enhan ced sub -clinical HHV replication 
might in turn affect the ability of this immuno -modulatory intervention to reduce 
inflammation during suppressive ART. Also, if increased reactivation occurs, then 
measures of asymptomatic HHV replication should be consider ed as a possible 
safety measure for future studies.  
 
Potential Impact of this Clinical Trial  
Chronic inflammation and immune activation promote end -stage organ disease leading 
to decreased survival in virologicall y suppressed individuals on ART. To date,  
interventions to mitigate this process are severely  lacking. Inhibition of the Jak -STAT 
pathway using a FDA -approved agent, ruxolitinib, provides an unprecedented 
opportunity to significantly attenuate levels of inflammation and such an approach may 
restore  the immunologic b alance. We hypothesize that Jak -STAT inhibitor treatment will 
result in higher CD4 + T cell counts as well as  lower levels of immune activation and 
chronic inflammation. We expect to observe decreased immune activation that will 
persist fo llowing discontinuation of ruxolitinib. We also posit that by “resetting” the 
immunologic balance in favor of less immune activation and inflammation, this 
immunologic milieu will persist in the absence of ruxolitinib. Since l ower levels of 
immune activati on and chronic inflammation have been associated with fewer AIDS and 
serious non -AIDS clinical events , we anticipate that long term use of  ruxolitinib could 
provide a tangible clinical benefit , i.e., increased event -free survival . Furthermore, we 
have show n in vitro that ruxolitinib has specific anti -HIV-1 properties even in resting 
CD4+ T cells and monocyte/macrophages, and can reduce homeostatic proliferation , 
which we expect will result in a decline of the HIV -1 reservoir. If successful, this study 
will be the first of its kind to demonstrate both lasting immunologic enhancement and 
impact on the HIV -1 reservoir.  
 
Justification for Proceeding with Studies in Humans with HIV -1 
Presently studies of ruxolitinib are being conducted on non -human primates (NHP)  
infected with simian immunodeficiency virus ( SIV) (both viremic and virologically 
 33 A5336  
FINAL  Version 2.0 
  05/21/15 
 
suppressed  on ART ). However, there is no guarantee that the PKs, safety profile , and 
efficacy of ruxolitinib in these models will correlate with humans infected with HIV -1.  
 
The dose selected for the NHP /SIV study is significantly lower than that which has 
already been dosed in other NHP  studies (Incyte Corporation  data). The dose being 
used in the NHP/ SIV study is also ca lculated to mirror the 10 mg BID  dosing in humans, 
which is well tolerated and low er than commonly prescribed doses  of 15, 20, or 25 mg 
BID. To that end, studies with prolonged dosing periods of ruxolitinib in the NHP have 
not been conducted previously. The dose selected herein for the  NHP study is designed 
to provide a balance between what we know is well tolerated in humans, and a safe level 
relative to what has  been dosed in NHP previously. More specifically, the dose to be 
used in the NHP  study has been calculated using the publis hed single dose PK  of 
ruxolitinib in NHP , allowing for mathemati cal scaling of NHP  dosing to match plasma 
PKs observed in humans for 10 mg BID dosing.  
 
The data obtained could provide a proof -of-principle for reduction in SIV or HIV induced 
inflammation and activation, but species  and virus differences dictate that results should 
not be used to modify human clinical studies. Differences between the SIV infected NHP   
model and humans, such as virus (HIV versus  SIV), cellular factors, co receptors/  
receptors, and generalized cross -species differences, dictate that this pilot NHP study 
will probably not yield information resulting in modification of the human clinical protocol. 
  
The NHP pilot study included  a total of four rhe sus macaques with viral loads >  200,000 
copies/mL , which wer e treated with 2.2  mg/kg ruxolitinib BID  via oral administra tion for a 
total of 6  weeks. Two monkeys were  administered add -in HAART [( -)-FTC, PMPA, and 
Kaletra] starting at week 4 of ruxolitinib administration. During the first dose of ru xolitinib, 
blood s amples were  collected at baseline (befo re drug), and 1, 2, 4, and 12 hour  post 
admini stration for PKs . Blood samples were  tested  once a week , thereafter , and plasma 
collected during the remainder of the stud y (6 weeks total). Samples (3 mL ) were  
aliquoted to collect whole blood (for measuring of integrated viral DNA in PBM Cs, 
monocytes and macrophages and cell associated immunology markers , e.g., D16, 
CD16 3, Ki67, HLA -DR, CD25, and CD38 . Plasma samples have been  stored at -70o C 
before being assayed to dete rmine concentratio ns of ruxolitinib, ( -)-FTC, PMPA , and 
Kaletra, and soluble activation markers , e.g., sCD14, IL -6, IL-1/b. CSF was  collected 
once per week to measure drug levels and viral loads.  
 
The safety profile of ruxolitinib in individuals with myelo fibrosis has been well -
documented and FDA -approved for this indication. Emerging data have shown that even 
fewer AEs have been reported in individuals without myelofibrosis (solid  tumors and 
RA). We believe that the population of individuals living with HI V-1 who would be eligible 
for this study is immunologically and hematologically “healthier” than individuals with 
myelofibrosis and therefore should have few AEs.  
 
Justification for the Participant  Population Selected  
 
Virologically Suppressed on ART  
In order to assess the impact of ruxolitinib on chronic inflammation and systemic immune 
activation, it was important to exclude the impact of ART on these same markers 
through mechanisms dependent on and independent of viral replication.  
 
 34 A5336  
FINAL  Version 2.0 
  05/21/15 
 
Age and CD4+ T Cell Criteria  
In order to minimize AEs associated with ruxoli tinib, we chose a participant  population 
with an adequate CD4 + T cell -count and within a safe age range , ≥ 18 to < 75. 
Furthermore, the immune sys tem of adults and children of ages outside of this ran ge 
behave differently , which could introduce additional confounders into the efficacy 
assessment.  
 
Exclusion of Pregnant Women  
Ruxolitinib has been designa ted pregnancy category C. In animal studies, treatment with 
ruxolitinib resulted in an increase in la te resorptions and reduced fetal weights at 
maternally toxic doses.  There are no adequate and well -controlled studies of ruxolitinib 
in pregnant women.  
 
Exclusion of Participant s with Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV) 
Infection  
Accor ding t o Incyte  Corporation , there are only five  participant s with HBV infection and 
no participant s with HCV inf ection who received ruxolitinib. Additionally, two case 
reports of HBV reactivation in individuals receiving ruxolitinib for myelo fibrosis were 
publis hed [ 61, 62 ]. Therefore , it was recommended that participant s with HBV infection 
or HCV infection be excluded from this study . 
 
Risk Benefit Assessment  
Ruxolitinib may have side effects, including thrombocytopenia, anemia, diarrhea, fever, 
infections, and fatigue and could resu lt in changes of ARV  concentrations. There are 
also risks associated with phlebotomy such as discomfort, bleeding, bruising and/or 
inflammation plus a small risk of infection. It is not known if ruxolitinib causes harm to the 
fetus. B y using a low dose of ruxolitinib , short treatment  duration , and choosing a 
population that has higher CD4 + T cell counts and that is not pregnant, we feel these 
risks have been minimized. This study is intended to explore how ruxolitinib could impact 
the immune system for individuals with virologic suppression on ART. There is no 
anticipated benefit for participants participating in this study. Information learned 
from this study may help others who have HIV -1 and are experiencing ongoing 
inflammation and systemic immune activation. For a further description of the potential 
impact of this study, refer to the section “Potential Impact of This Clinical Trial”  (see 
above ). 
 
 
3.0 STUDY DESIGN  
 
A5336 is a randomized, open -label, prospective, 2 -arm (phase IIa) study that will enroll 
60 HI V-1 infected participant s (≥ 18 to < 75 years of age) who have been virologically 
suppressed fo r at least 2 years  (defined below  in section 4.1.3 ), have CD4+ T cells >  
350 cells/mm3 ≤ 30 days prior to study entry,  and have plasma  HIV-1 RNA below the 
limit of detection ≤ 30 days prior to entry. Participant s will be randomized at a 2:1 ratio 
to either Arm A (treatment with ruxolitinib) or Arm B ( no study treatment ) (40 and 20 in 
the ruxolitinib and no study treatment arms, respectiv ely). Participant s in Arm A will 
receive treatment with ruxolitinib 10 mg BID for 5 weeks. Based upon the mechanism of 
action for ruxolitinib, it is not expected that the plasma viral load will increase. However, 
as a safety precaution, participant s will b e monitored for changes in HIV -1 viral load. If 
changes in inflammatory markers are observed  and/or if there are advances in the field 
 35 A5336  
FINAL  Version 2.0 
  05/21/15 
 
which might provide further rationale for assessing the virologic endpoints in the 
absence of achieving the desired immun ologic outcomes , we will assess for changes in 
the HIV -1 reservoir (specifically plasma HIV -1 RNA by single copy assay, cellular HIV-1 
RNA and total DNA , 2 LTRs , and integrated DNA).  Refer to section 6.1, Schedule of 
Events  (SOE) , for specific evaluations  and time points. Participant s in Arm A will be 
followed for 7 weeks  after discontinuation of ruxolitinib, and will be on study for a total of 
12 weeks.  Participant s in Arm B will be followed on -study for 12 weeks.  
 
 
4.0 SELECTION AND ENROLLMENT OF PARTICI PANT S 
 
4.1 Inclusion Criteria  
 
4.1.1  HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or 
chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry 
and confirmed by a licensed Western blot or a second antibody t est by a method 
other than the initial rapid HIV and/or E/CIA, or by HIV -1 antigen,  or historical 
plasma HIV -1 RNA viral load . 
 
NOTE: The term “licensed” refers to a US FDA-approved kit, which i s required for 
all IND studies.  
 
WHO (World Health Organizatio n) and CDC (Center s for Disease Control and 
Prevention) guidelines mandate that confirmation of the initial test result must 
use a test that is different from the one used for the initial assessment. A reactive 
initial rapid test should be confirmed by eit her another type of rapid assay or an 
E/CIA that is based on a different antigen preparation and/or different test 
principle ( eg, indirect versus competitive), or a Western blot or a plasma HIV -1 
RNA viral load.  
 
4.1.2 CD4+ T cell count > 350 cells/mm3 ≤ 30 days prior to study entry  at any US 
laboratory that has a CLIA (Clinical Laboratory Improvement Amendments) 
certification or its equivalent.  
 
4.1.3 Documentation of virologic suppression defined as:  
 
(a) at least two historical HIV-1 RNA < 50 copies/ mL using FDA -approved assay 
performed by any laboratory that has a CLIA certification or its equivalent while 
on ART , one of which was obtained between 336 to 31  days , inclusive , prior to 
study en try and one obtained between 337  and 730 days , inclusive , prior to study 
entry,   
(b) no HIV -1 RNA values ≥ 50 copies/mL using a FDA -approved assay 
performed by any laboratory that has a CLIA certification or its equivalent within  
336 days , inclusive , prior to study entry , and  
(c) not more than one HIV -1 RNA value  equal to or greater than 50 and less than 
or equal to 200 copies/mL  from a result obtained between 337  and 730 days , 
inclusive , prior to study entry  (and no HIV -1 viral load above 2 00 copies/mL) .  
 
 36 A5336  
FINAL  Version 2.0 
  05/21/15 
 
4.1.4  Screening p lasma HIV -1 quantitative RNA below the limit of detection using an 
FDA-approved assay with a lower limit of quantification < 50 copies/mL (e.g., < 
40 copies/mL obtained by  the Abbott Real -Time assay or  20 copies/mL by the 
Roche Taqman v2.0 assay) performed by any laboratory that has a CLIA 
certification or its equivalent obtained ≤ 30 days prior to study entry . 
 
4.1.5  Tuberculosis (TB) screening within 365 days of the screening visit  
diagnosed by tuberculin skin test or interferon gamma release assay.  
  
4.1.6 Currently o n continuous ART for at least 730 days  prior to study entry, d efined as 
continuous ART for the 730 days period , inclusive,  prior to study entry with no 
ART interruption longer than 7 consecutive days.  
 
NOTE:  The current regimen must include  tenofovir/emtricitabine ( TDF/FTC ) or 
abacavir/lamivudine ( ABC/3TC ) + a nonnuc leoside reverse transcriptase inhibitor 
or integrase strand transfer inhibitor (NNRTI or INSTI, not containing cobicistat) 
for at least 60 days , inclusive , prior to study entry . 
 
4.1.7 The following  laboratory values obtained ≤ 30 days prior to entry by any US 
laboratory that has a CLIA c ertification or its equivalent:  
 
 Absolute neutrophil count ( ANC ) ≥ 1000 /mm3 
 Hemoglobin  ≥ 12.0 g/dL 
 Platelets ≥  200,000/mm3 
 Calculated c reatinine  clearance  (CrCl ) ≥ 80 mL/min (by Cockcroft Gault  
equation) . NOTE: A calculator for estimating the CrCl can be found at 
www.fstrf.org/ACTG/ccc.html  
 Aspartate  aminotransferase (AST) (SGOT) ≤  1.5x ULN  
 Alanine aminotransferase (ALT) (SGPT) ≤  1.5x ULN  
 Alkali ne phosphatase ≤  1.5x ULN  
 
4.1.8 For fe males of reproductive potential (defined as women who have not been 
post-menopa usal for at least 24 consecutive months, i.e., who have had menses 
within the preceding 24 months, or women who have not undergone surgica l 
sterilization, specifically hysterectomy and/or bilateral oophorectomy or bilateral 
salpingectomy) must have a  negative serum or urine pregnancy test with a 
sensitivity of 25 mIU/mL within 72 hours , inclusive,  prior to study entry.   
 
4.1.9 All participan ts must agree not to participate in a conception process (e.g., 
active attempt to become pregnant or to impregnate, sperm donation, in vitro  
fertilization).  
 
4.1.10 All participant s of reproductive potential, who are participating in sexual activity 
that c ould lead to pregnancy, must agree to use at least one reliable method of 
contracepti on while receiving the study drugs and for 7 weeks a fter stopping the 
medications. Acceptable forms of contraceptive  include:  
 
 Condoms (male or female) with or without a s permicidal agent  
 Diaphragm or cervical cap with spermicide  
 37 A5336  
FINAL  Version 2.0 
  05/21/15 
 
 Intrauterine device (IUD)  
 Hormone -based contraceptive (must contain at least 35 mcg of ethinyl 
estradiol)  
 
4.1.11 Women who are not of reproductive potential (women who have been post -
menopausal fo r at least 24 consecutive months or have undergone hysterecto my 
and/or bilateral oophorectom y or salpingectom y) or men who have documented 
azoospermia or undergone vasectomy are eligible to start study drugs without 
requir ing the use of contraceptives. Acceptable documentation of sterilization and 
menopause is specified belo w. 
 
Written or oral documentation communicated by clinician or clinician’s staff of 
one of the following:  
 
 Physician report/letter  
 Operative report or other source documentation in the p atient record (a 
laboratory report of azoospermia is required to document successful 
vasectomy)  
 Discharge summary  
 Follicle stimulating hormone -release factor (FSH) measurement elevated into 
the menopausal range as established by the reporting laboratory.  
 
4.1.12 Men and women age  18 and <  75 years . 
 
4.1.13 Ability and willingne ss of participant  or legal representative to provide  written 
informed consent  and attend study visits as scheduled at a participating site . 
 
4.2 Exclusion Criteria  
 
4.2.1 A current  or past history of progressive multifocal l eukoencephalopathy . 
 
4.2.2 Breast feeding  or pregnancy .  
 
4.2.3 Use of strong  inhibitors or inducers of  CYP3A4 including a protease inhibitor, 
cobicistat or entry inhibitor s as part of the current ART regimen or o ther 
concomitant therapy.   
 
4.2.4 Known allergy/sensitivity or any hypersensitivit y to components of study drug  or 
their formulation . 
 
4.2.5 Active drug or alcohol use or dependence that, in the opinion of the site 
investigator, would interfere with adhere nce to study requirements . 
 
4.2.6 Acute or s erious illness or infection requiring systemic treatment and/or 
hospitalization  within 60 days prior to entry . 
 
4.2.7 Vaccinations (other than influenza) ≤ 30 days prior to the study entry visit.  
 
 38 A5336  
FINAL  Version 2.0 
  05/21/15 
 
NOTE: Influe nza vaccine  is permitted. Participant s are encouraged to get this 
vaccine ≥ 7 days prior to the study pre -entry visit.  
 
4.2.8 Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), systemic 
cytotoxic chemotherapy  or investigational therapy  ≤ 60 days prior to study entry.   
  
4.2.9 Any current diagnosis or past history of a significant pulmonary , 
neurologic,  cardiac, renal , or hepatic disorder prior to study entry , excluding 
treated HIV or treated hypertension. Diagnoses that would lead to 
exclusion include, but are not limited to  the following : 
 CDC categ ory C AIDS -indicator conditions  
NOTE  A: Except HIV encephalopathy, HIV wasting, esophageal 
candidiasis, or pneumocystis pneumonia without dissemination . 
NOTE  B: List available : 
http://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm  
 Varicella zoster  
 Lymphoproliferative malignancy  
 Chronic or severe psychiatric condition  
 Chronic liver disease  of any etiology and any degree of se verity.  
 Chronic hepatitis  
 Disseminated fungal infection of any type or duration that is not limited 
to cutaneous or mucocutaneous surfaces  
 A medical disorder that predisposes to bleeding  
NOTE: If a site investigator is unsure of whether a history of a 
significant medical or psychiatric condition should lead to participant  
exclusion, the investigator should err on the side of safety if s/he 
believes that an active or clinically resolved disorder may put the 
participant  at risk from participation in the stu dy, influence the results 
of the study , or affect the participant ’s ability to participate. If still 
uncertain, then the site should contact the protocol team 
(actg.corea5336@fstrf.org ) to assist in a determination.  
 
4.2.10 Change in the ART regimen within 12 weeks , inclusive,  prior to study entry or 
intended modification of ART during the study.  
 
NOTE: Modificati ons of ART doses during the 12 weeks prior to study entry are 
permitted. In addition, the change in formulation (e.g., from standard formulation 
to fixed -dose combination) is allowed within 12 weeks prior to study entry. A 
within class single drug substitu tion (e.g., switch from nevirapine to efavirenz or 
from atazanavir to darunavir) is allowed within 12 weeks prior to study entry, with 
the exception of a switch between any other NRTI to/from abacavir. No other 
changes in ART within the 12 weeks prior to s tudy entry are permitted.  However, 
participants need to be receiving (and tolerating) an allowable (for study 
purposes) ART regimen for at least 4 weeks prior to study entry.  
 
4.2.11 History of untreated latent tuberculosis infection (LTBI) diagnosed by  
  tuberculin skin test or interferon gamma release assay. LTBI treatment  
  would consist of 9 months of isoniazid or an equivalent therapy  completed at  
  least 4 weeks prior to study entry .  
 39 A5336  
FINAL  Version 2.0 
  05/21/15 
 
4.3 Study Enrollment Procedures  
 
4.3.1  Prior to implementation of this protocol, and any subsequent full version 
amendments, each site must have the protocol and the protocol consent form(s) 
approved, as appropriate, by their local institutional review board (IRB)/ethics 
committee (EC) and any other applicable regulatory enti ty (RE). Upon receiving 
final approval, sites will submit all required protocol registration documents to the 
DAIDS Protocol Registration Office (DAIDS PRO) at the Regulatory Support  
Center (R SC). The DAIDS PRO will review the submitted protocol registrati on 
packet to ensure that all of the required documents have been received.  
Site-specific informed consent forms (ICFs) WILL  be reviewed or approved by 
the DAIDS PRO, and sites will receive an Initial Registration Notification when 
the DAIDS PRO receives a  complete registration packet.  Receipt of an Initial 
Registration Notification indicates successful completion of the protocol 
registration process. Sites will not receive any additional notifications from the 
DAIDS PRO for the init ial protocol registrati on. A copy of the Initial Registration 
Notification should be retained in the site's regulatory files.   
 
Upon receiving final IRB/EC and any other applicable RE approvals for an 
amendmen t, sites should implement the amendment immediately. Sites are 
require d to submit an amendment registration packet to the DAIDS PRO at the 
RSC. The DAIDS PRO will review the submitted protocol registration packet to 
ensure that all the required documents have been receive d. Site -specific ICF(s) 
WILL NOT be reviewed and appro ved by the DAIDS PRO , and sites will receive 
an Amendment Registration Notification when the DAIDS PRO receives a 
complete registration packet. A copy of the Amendment Registration Notification 
should be retained in the site's regulatory files.  
 
For additi onal information on the protocol registration process and specific 
documents required for initial and amendment registrations, refer to the current 
version of the DAIDS Protocol Registration Manual.   
 
Once a candidate for study entry has been identified, d etails will be carefully 
discussed with the participant . The participant  will be asked to read and sign 
the approved  protocol consent form . For participant s from whom a signed 
informed consent has been obtained, an ACTG Screening Checklist  must be 
entered through the Data Management Center (DMC) Participant  Enrollment 
System.  
  
4.3.2  Randomization/ Participant  Registration  
 
Participant s who meet enrollment criteria will be registered to the study 
according to standard ACTG DMC procedures. For participant s from whom 
informed consent has been obtained,  but who are deemed ineligible or who do 
not enroll into the initial protocol step,  an ACTG Screening Failure Results form  
must be completed and keyed into the database .  
 
 
 
 
 40 A5336  
FINAL  Version 2.0 
  05/21/15 
 
4.4 Coenrollment Guidelines   
 
 Sites are enco uraged to coenroll participant s in A5128 , “Plan for Obtaining  
Informed  Consent  to Use Stored  Human  Biological  Materials  (HBM) for Currently  
Unspecified  Analyses ,” and A5351s, “Effect of Immune -Modulatory Interventions 
on Cytomegalovirus Replication during Suppressive Antiretroviral Therapy”  
 Coenrollment in  A5128 and A5351s does not require permission from the A5336  
protocol chairs .  
 For specific questions and approval  for coenrollment in other studies,  sites should 
contact the protocol team  via e -mail as de scribed i n the Study Management section.  
 
 
5.0 STUDY TREATMENT   
 
5.1 Regimens, Administration, and Duration  
 
Study treatment is defined as ruxolitinib. Participant s will be randomized at a 2:1 ratio to 
either 5 weeks of treatment with ruxolitinib or  no stu dy treatment  as follows:  
 
ARM A:  Ruxolitinib  10 mg PO BID with or without food. Participants  must remain on 
ART regimen (not provided by the study) for the duration of the study.  
 
ARM B:  No study treatment.  Participants should be  encouraged to remain on  ART 
regimen for the duration of the study.  
 
Participant s in Arm A should be instructed not to drink grapefruit juice or eat 
grapefruit while taking ruxolitinib. Participant s will remain on study treatment  for five 
weeks and be followed for seven weeks aft er treatment discontinuation. Participant s 
will be on study for  a total of  12 weeks.  
 
5.2 Study Product Formulation and Preparation  
 
Ruxolitinib tablets 10mg should be stored at room temperature be tween 20º and 25ºC 
(68º and 77º F). Excursions  permitted bet ween 15ºC and 30ºC (59ºF and 86º F). See 
USP controlled room temperature.  
 
5.3 Pharmacy: Product Supply, Distribution, and Accountability  
 
5.3.1  Study Product Acquisition /Distribution  
 
Ruxolitinib , manufactured by Incyte Corporation,  will be provided by Emo ry 
University and available through the NIAID Clinical Research Products 
Management Center  (CRPMC) . The site pharmacist should obtain the study 
product (s) for this protocol by following the instructions  in the manual Pharmacy 
Guidelines and Instructions fo r DAIDS Clinical Trials Network s.  
 
 
 
 41 A5336  
FINAL  Version 2.0 
  05/21/15 
 
5.3.2  Study Product Accountability  
 
The site pharmacist is required to maintain complete records of all study products 
received from the NIAID CRPMC  and subsequently dispensed. All unused study 
products  in CRSs  must be  returned to the NIAID CRPMC  (or as otherwise 
directed by the sponsor) after the study is completed or terminated. The 
procedures to be followed are in the manual Pharmacy Guidelines and 
Instructions for DAIDS Clinical Trials Network s.  
 
5.4 Concomitant Me dications  
 
Whenever a concomitant medication or study agent is initiated or  a dose changed, 
investigators must review the concomitant medication ’s and study agent ’s most recent 
package insert, Investigator ’s Brochure, or updated information from DAIDS to o btain the 
most current information on drug interactions, contraindications, and precautions.  
 
Additional drug information may be found on the updated ACTG Drug Interactions 
Database  located at:  http://tprc.pharm.buffalo.edu/home/di_search/     
 
5.4.1  Prohibited Medications  
 
A list of prohibited medications can be found on the protocol -specific web page 
(PSWP), https://membe r.actgnetwork.org/study/53292#profile=4 . 
 
 
5.4.2  Precautionary Medications  
 
A list of precautionary medications is posted on the PSWP , 
https://member.actgnetwork.org/study/53292#profil e=4. 
 
 
 
 42 A5336  
FINAL  Version 2.0 
  05/21/15 
 
6.0 CLINICAL AND LABORATORY EVALUATIONS  
 
6.1 Schedule of Events  
 
Evaluation  Screenin g Pre-Entry  Entry  On-Study Evaluations  
(Weeks ) 
Confirmation 
of Virologic 
Failure  Premature 
Treatment/Study  
Discontinuation 
Evals.  1 2 4 5 10 12 
Window  ≤30 days 
before  
entry  
 ≥24 hours 
after 
screening and 
≤7 days 
before  entry   ± 3 days  ± 7 days  
Documentation of HIV -1 X           
Medical History  X  X         
Medication History  X  X         
Complete Physical 
Examination   X          
Targeted Physical  
Examination  X  X X X X X X X  X 
Clinical Assessments    X X X X X X X  X 
Concomitant Medications  X  X X X X X X X  X 
Study Treatment 
Modifications  X  X X X X X X X  X 
ART Modifications  X  X X X X X X X  X 
Hematology  X  X X X X X X X  X 
Liver Function  Tests  X  X X X X X X X  X 
Blood Chemistries  X  X X X X X X X  X 
Fasting Lipid Panel    X    X    X (if prior to 
week 5)  
Pregnancy Testing  X  X1 If suspected    
Nadir CD4+ T cell Count    X      
Documentation of Pre -
ART CD4+ T cell Count    X      
CD4+/C D8+ X X2 X  X  X  X  X 
 43 A5336  
FINAL  Version 2.0 
  05/21/15 
 
Evaluation  Screenin g Pre-Entry  Entry  On-Study Evaluations  
(Weeks ) 
Confirmation 
of Virologic 
Failure  Premature 
Treatment/Study  
Discontinuation 
Evals.  1 2 4 5 10 12 
Window  ≤30 days 
before  
entry  
 ≥24 hours 
after 
screening and 
≤7 days 
before  entry   ± 3 days  ± 7 days  
Stored PBMC s for Other 
Immunologic Studies    X    X  X  X 
Stored Plasma Soluble 
Markers   X X   X X  X  X 
Stored Plasma Soluble 
Marker:IL -6  X X   X X X X  X 
Documentation of Pre-
ART HIV -1 RNA    X         
Plasma HIV-1 RNA  X  X  X  X  X X X 
Stored Plasma HIV -1 RNA 
for Single Copy Assay    X    X  X  X 
Stored PBMC Reservoir 
Assay s   X    X  X  X 
Stored Plasma/PBMC   X X  X  X  X  X 
Stored Oral Swabs for 
HHV   X X X X X X X X  X 
Plasma  PK  Collection for 
Arm A     X  X     X (if prior to week 
4) 
Medication Diary for Arm A 
(D=Distribute; C=Collect)    X (D)  X (C)  X 
(D) X (C)      X (C) (if prior to 
week 4)  
Adherence  Assessment     X X X X X X X  X 
 
1Refer to section 6.2.2 for pregnancy testing at study entry.  
2Only one CD4 +/CD8 + is required if screening and pre -entry visits are combined.  
 44 A5336  
FINAL  Version 2.0 
  05/21/15 
 
6.2 Timing of Evaluations  
 
6.2.1  Screening and  Pre-Entry Evaluations   
 
Screening and pre -entry evaluations must occur prior to the participant  starting 
any study medications, treatments, or interven tions.  
 
Screening  
Screening evaluations to determine eligibility must be completed within 30 days 
prior to study entry unless otherwise specified.  In addition to data being collected 
on participant s who enroll into the study, demographic, clinical, and lab oratory 
data on screening failures will be captured in a Screening Failure Results form  
and entered into the ACTG database.  
 
Pre-Entry   
Pre-entry e valuations must be completed at least 24 hours  after screening 
evaluations have been completed  and within 7 days prior to  the entry visit . 
 
The pre -entry and screening visits may be combined in the event the participant  
presents with the following: Documentation of HIV -1 status and the results of an 
HIV-1 RNA level performed at a CLIA -certified laboratory ≤ 30 days prior to study 
entry.  
 
6.2.2  Entry  Evaluations  
 
Entry ev aluations must occur at least 24 hours  after pre -entry /screening  
evaluations unless otherwise specified . All entry evaluations must be performed 
after successful randomization  and completed prior to the initiation of study 
treatment . If needed , the pregnancy testing at screening can be accepted for the 
entry value if the screening value was obtained within 72 hours of entry . All 
participant s must begin treatment within 72 hours  after enrollment.  
 
6.2.3  Post-Entry Evaluations  
 
On-Treatment Evaluations   
Evaluatio ns must occur after randomization . Study visits must be scheduled on 
the weeks indicated in section 6.1, within the visit windows.  
 
The week s 1 through  5 study visit s must be scheduled per section 6.1, the SOE  
table  ± 3 days.  
 
Please note influenza vaccination is prohibited ≤  7 days prior to all study visits.  
The study visit will need to be rescheduled if the influenza vaccine was 
given ≤ 7 days prior to a study visit. All other vaccinations are prohibited 
throughout the duration of the study.  
 
 45 A5336  
FINAL  Version 2.0 
  05/21/15 
 
Post-Treatment Ev aluations   
There will be 7 additional weeks of follow -up after 5 weeks of study treatment. 
Participant s will undergo evaluations as outlined at weeks 10 and 12 in section 
6.1. The week 10 and 12 study visits must be scheduled per the SOE ± 7days. 
Week 12 i s the final study visit.   
 
NOTE: Participant s who discontinue treatment prematurely are followed on 
study/off treatment until study completion, i.e., week 12.  
 
Virologic Failure  
For participant s who have suspected virologic failure, base d on an HIV -1 RNA  
level above the lower limit of quantification , the site should query the participant  
about intercurrent vaccination, acute illness, or identified periods of 
nonadherance. If one of these conditions is suspected to account for the 
increased HIV -1 RNA , then no further evaluation is necessary until the next study 
visit. If none of these factors are present, a confirmatory H IV-1 RNA should be 
done within 7 days  of receipt of the results of the first t est. If the repeat HIV -1 
RNA is  below the assay limit of qua ntification , then no fu rther evaluation is 
necessary. See section 7. 5 for management of confirmed virologic failure.   
 
6.2.4  Discontinuation Evaluations  
 
Evaluations for Randomized or Registered Participant s Who Do Not Start Study 
Treatment  
All CRFs must be com pleted and keyed for the p eriod up to and including entry . 
No further follow up is required for participant s randomized to Arm A who do not 
start study treatment.  
 
Premature Treatment Discontinuation Evaluation s  
Participant s who prematurely discontinue th e study treatment prior to week 5 
should complete the premature treatment discontinuation evaluations within 14 
days after discontinuing treatment. Participant s will then be followed on study/off 
study treatment.  
 
Site personnel should notify the protocol  core team ( actg.corea5336@fstrf.org ) 
within 48 hours of any participant  who prematurely discontinues the study 
treatment.  
 
Premature Study Discontinuation Evaluations  
 Participant s who prematurely discontin ue the study will have the  
premature treatment/study discontinuation evaluations performed prior to being 
taken off the study.  
 
Site personnel should notify the protocol core team ( actg.corea5336@fstrf.org ) 
within 48 hours of any participant  who prematurely discontinues the study.  
 
 46 A5336  
FINAL  Version 2.0 
  05/21/15 
 
Pregnancy  
Pregnancy will result in immediate and permanent discontinuation of the study 
treatment . Please see section 7. 4 for detailed information regarding participant  
management.  
 
6.3 Instructions  for Evaluations  
 
All clinical and laboratory information required by this protocol is to be present in the 
source documents. Sites must refer to the Source Document Guidelines on the  DAIDS  
Web site for information about what must be incl uded in the source document:  
http://www.niaid.nih.gov/labsandresources/resources/daidsclinrsrch/documents/sourced
ocappndx.pdf . 
 
All stated evaluations are  to be recorded on the CRF and keyed into the database  
unless otherwise specified . This includes events that meet the International Conference 
on Harmonisation (ICH) definit ions for a SAE : 
 
 Results in death  
 Life-threatening  
 Requires inpatient ho spitalization or prolongation of existing hospitalization  
 Results in persistent or significant disability/incapacity  
 Congenital anomaly/birth defect  
 Other important medical event (may not be immediately life -threatening or result in 
death or hospitalizati on but may jeopardize the patient or may require intervention to 
prevent one of the events listed above ).   
 
To grade diagnoses, signs and symptoms, and laboratory results, sites must refer to the 
DAIDS Table for Grading the Severity of Adult and Pediatric  Adverse Events (DAIDS AE 
Grading Table), Version  2.0, November 2014 , which can be found on the DAIDS R SC 
Web site: http://rsc.tech -res.com/safetyandpharmacovigilance/ .   
 
6.3.1  Documentation of HIV -1 
 
Section 4.1.1 specifies  assay requirements for HIV -1 documentation.  HIV-1 
documentation is not recorded on the CRF.  
 
6.3.2  Medical History  
 
The medical history must  include all diagnoses identified by the ACTG criteria for 
clinical eve nts and other diagnoses.  In addition to reporting all diagnoses within 
the past 30 days, the following diagnoses should be reported regardless of when 
the diagnosis was made.   
 
 AIDS -defining conditions  
 Bone fractures (verbal history accepted ) 
 Coronary hear t disease  
 Cancer (exclusive of basal/squamous cell skin cancer)  
 Diabetes  
 47 A5336  
FINAL  Version 2.0 
  05/21/15 
 
 Tuberculosis  
 Chronic  or acute HCV  
 Chronic  or acute HBV 
 HIV encephalopathy  
 HIV wasting  
 Esophageal candidiasis  
 Pneumocystis pneumonia without dissemination  
 
Any allergies to any medicat ions and their formulations must also be 
documented.   
 
6.3.3 Medication History  
 
A medication history must be present, including start and stop dates. The table 
below lists the medications that must be included in the history.  
 
Medication Category  Complet e History or Timeframe  Record on 
CRFs  
ART Complete history (estimated dates if the 
exact dates cannot be obtained)  Yes 
Immune -based therapy  Complete history (estimated dates if the 
exact dates cannot be obtained)  Yes 
HIV-1-related vaccines  Complete hist ory Yes 
Prescription drugs for treatment 
of opportunistic infections  Within 30 days prior to study entry  Yes 
Prescription drugs for 
prophylaxis of opportunistic 
infections  Within 30 days prior to study entry  Yes 
Prescription drugs : All including 
statins , anticoagulation therapy, 
NSAIDS, a nti-inflammatory 
drugs not considered immune 
based therapy  Within 30 days prior to study entry  Yes 
Alternative therapies  Within 30 days prior to study entry  Yes 
Dietary supplements  Within 30 days prior to study entry  Yes 
Aspirin use  Documentation of any aspirin use over a 
period of more  
than 5 days in any given week, taken 
within 30 days prior to study entry  Yes 
 
6.3.4 Physical Examinations  
 
Complete Physical Exam  
A complete physical examination  is to include at a mi nimum an examination of 
the skin, head, mouth , and neck; auscultation of the chest; cardiac exam; 
abdominal exam; examination of the lower extremities for edema ; and Karnofsky 
performance score . The complete physical exam will also include signs and 
 48 A5336  
FINAL  Version 2.0 
  05/21/15 
 
sympto ms, diagnoses, and vital signs  (temperature, pulse,  respiration rate,  and 
blood pressure ). 
 
Targeted Physical Exam  
A targeted physical examination  is to include vital signs (temperature, pulse , 
respiration rate, and blood pressure) and is to be driven by a ny previously 
identified  diagnoses or new  signs or symptoms that the participant  has 
experienced within 30 days prior to entry or since the last visit.  
 
6.3.5  Clinical Assessments  
 
Height  
Height (in cm) will be measured at the entry  visit.  
 
Weight  
Weight (in kg) will be measured at screening, entry and at all subsequent study 
visits . 
 
Signs and Symptoms  
At entry , all grades that occurred  30 days before entry must be recorded; p ost-
entry,  only signs and symptoms Grade  2 must be recorded  except record all 
non-traumatic bruising regardless of grade . All G rade 3 or higher sign/symptom, 
any sign/symptom regardless of grade that led to a change in treatment, or that 
met ICH, EAE , or SAE guidelines, are defined by the protocol as reportable 
events that will requ ire more detailed event reporting  and must be reported on 
the CRF within 2 business days . 
 
Diagnoses  
At entry and on -study visits, record all diagnoses identified by the ACTG  criteria  
and any of the following targeted diagnoses  occurr ing since the last stu dy visit : 
 New onset seizures; or physician diagnosed CNS  abnormality .  
 
Post entry diagnoses must be reported on the CRF within 2 business days.  
 
6.3.6  Concomitant Medications  
 
Record in source documents and CRFs  additions or discontinuations of any  
prescr iption medication s and any medication or supplement included in the 
precautionary medication list (Se e PSWP ). Record on the source documents 
and CRFs use of aspirin (chronic use only, defined as daily aspirin use over a 
period of more than 5 days in any gi ven week) since the last study visit, including 
actual or estimated start dates and stop dates.   
 
6.3.7  Study Treatment  Modifications  
 
Record  all study drug modifications, including initial doses , participant -initiated 
and/or protocol -mandated  modificatio ns, inadverten t and deliberate interruptions , 
and permanent discontinuation of treatment at each visit . Participant  missing 
 49 A5336  
FINAL  Version 2.0 
  05/21/15 
 
greater than 3 doses of study drug per week for two or more weeks result s in a 
study treatment discontinuation  and should be recorde d on the CRF . The 
protocol core  team ( actg.corea5336@fstrf.org ) must be notified of any permanent 
discontinuation of study drug.  
 
6.3.8  ART Modifications  
 
Record all modifications, including initial doses, participant -initiated and/or 
protocol -mandated modifications, inadvertent and deliberate  interruption  of 7 
days or more  and permanent discontinuation.  
 
Arm A participant s who change or discontinue ART must prematurely 
discontinue study treatment  and be foll owed on study/off study treatment . Refer 
to protocol section 6.2.4 for premature treatment discontinuation evaluations.  
 
6.3.9 Laboratory Evaluations  
 
All laboratory evaluations at entry and week 5 study visit must be collected in a 
fasting state (8 -hour f ast with exception of water and medications). If 
participant s are in a non -fasting state at the time of the study visit, they should 
return to the clinic within 72 hours for a fasting blood draw.  
 
 At screening  and entry  all laboratory values  must be record ed.  
 For post -entry assessments, record all Grade  2 laboratory values, except 
for estimated CrC l, creatinine, AST (SGOT), ALT (SGPT), ANC, hemoglobin, 
and platelet count . These values should be recorded at every visit  regardless 
of grade .  
 All grade 3 or  higher laboratory values, any laboratory value that led to a 
change in treatment or that met ICH, EAE , or SAE guidelines are defined by 
the protocol as reportable events that will requir e more detailed event 
reporting and must be reported on the CRF withi n 2 business days.  
 
Although specific virologic and immunologic assays are described below, newer 
technology may preclude the utility of these assays and , therefore , this protocol 
will allow for the more advanced assays to be performed instead.  
 
Hematolog y 
Hemoglobin, hematocrit, red blood cells (RBC), mean corpuscular volume 
(MCV), white blood cell s (WBC ), differential WBC, absolute neutrophil count 
(ANC), platelets.  
 
Liver Function Tests  
AST (SGOT), ALT (SGPT) , alkaline phosphatase, indirect bilirubin, d irect 
bilirubin, and total bilirubin .  
 
NOTE: Indirect bilirubin may be calculated from the total and direct bilirubin 
values.  
 
 50 A5336  
FINAL  Version 2.0 
  05/21/15 
 
Blood Chemistries  
Electro lytes (sodium, potassium , chloride, bicarbonate ), glucose, creatinine,  
blood urea nitrogen (BUN)  and CrCl as estimated by the Cockcroft -Gault 
equation .  
 
NOTE:  A calculator for esti mating the CrCl can be found at: 
https://www.fstrf.org/apps/cfmx/apps/common/Portal/ index.cfm?event=postLogin . 
 
Fasting Lipid Panel  
Cholesterol, triglyceride, high -density lipoprotein (HDL), low -density lipoprotein 
(LDL).  If the LDL cannot be calculated due to elevated triglyceride levels, a 
direct LDL should be measured.  
 
Pregnancy Tes ting 
For women with reproductive potential: Serum or urine -HCG (urine test must 
have a sensitivity of 25 mIU/mL).  
 
6.3.10 Nadir CD4+ T cell Count  
 
The participant ’s prior nadir CD4+ T cell count (absolute value and date) should 
be documented when possibl e with a copy of the nadir CD4+ T cell count report. 
If this documentation is not available, then participant  recollection will suffice. 
For participant s who do not know the exact nadir value and for whom there is 
no source documentation, then recall of  the categorical nadir (e.g., <  50, <  100, < 
200 cells/mm3) will suffice.    
 
6.3.11  Documentation of Pre -ART CD4+ T cell Count  
 
Record on the CRF  the documented date and level of the participant ’s pre-ART 
CD4+ T cell count that w as obtained most immediately p rior to a participant ’s 
initiating ART.  If documentation is not available, then participant  recollection will 
suffice.  
 
6.3.12  Immunologic Studies  
 
CD4+/CD8 + 
At screening, pre-entry and for all on -study evaluations o btain absolute 
CD4+/CD8+ count and perc entages from a laboratory  that possess es a CLIA 
certification or equivalent  and is certified for protocol testing by the DAIDS 
Immunology Quality Assurance (IQA) Program.  Note only one CD4+/CD8+ 
value is needed if the screening and pre -entry visits are com bined.  
 
Because of the diurnal variation in biomarkers that may be measured as part of 
the study (e.g., CD4+ and CD8+ T cell counts and other biomarkers that may be 
measured on stored samples), blood draws for individual participant s should be 
performed co nsistently in either the morning or the afternoon throughout the 
study, if possible.  
 
 51 A5336  
FINAL  Version 2.0 
  05/21/15 
 
6.3.1 3 Stored PBMCs  for Other Immunologic Studies  
 
PBMCs will be collected and stored at the indicated visits per section 6.1  (see 
Laboratory Processing Chart [L PC] for more information) for potential 
comparative assessment of:   
 
 At specified time points, cellular (macrophage/monocytes and lymphocytes) 
markers of immune activation and inflammation in the peripheral blood 
including but not limited to HLA -DR, CD16 +, CD38, CD56, CD69 , and 
CD14+CD16+  monocyte levels will be de termined using flow cytometry and 
using stored specimens at the end of the study.  
 
 Lymphocyte markers of immune activation in the peripheral blood including 
but not limited to HLA -DR, CD38, CD69, and CD 14+/CD16+ monocyte levels 
using microarray panels for both mRNA and protein expression.   
 
 Macrophage/monocyte markers of immune activation and inflammation in the 
peripheral blood including but not limited to HLA -DR, CD38, CD69, and 
CD14+CD16+ monocyte le vels using microarray panels for both mRNA and 
protein expression.  
 
6.3.1 4 Stored Plasma  Soluble Markers  
 
Plasma for stored soluble markers will be collected and stored at the indicated 
visits per section 6.1 (see LPC for  more information) for  comparative assessment 
of: 
 
 Soluble markers of immune activation and inflammation in the peripheral 
blood inc luding but not limited to sCD14, TNF -α, IL-1α, IL-18, IL-1β, mCSF, 
and neopterin will be determined using enzyme -linked immunoassay  using 
stored specimens at t he end of the study .  
 
 Soluble markers of immune activation and inflammation in the peripheral 
blood inc luding but not limited to sCD14, TNF -α, IL-1α, IL-1β, mCSF , and 
neopterin using microarray panels.  
 
6.3.15  Stored Plasma Soluble Marker: IL -6 
 
 Plasma f or stored soluble marker IL -6 will be collected and stored at the  
 indicated visits per section 6.1.  
 
6.3.16  Documentation of Pre-ART HIV -1 RNA  
 
Record on the CRF the documented date and level of the participant ’s pre-ART 
viral load  that was obtained immediately prior to a participant ’s initiating ART . If 
documentation is not available, then participant  recollection will suffice.  
 
 
 52 A5336  
FINAL  Version 2.0 
  05/21/15 
 
6.3.17 Virologic Studie s 
 
Plasma HIV -1 RNA  
Screening HIV -1 RNA must be performed within 30 days prior to  study entry . All 
HIV-1 RNA determinations must be done  using an FDA -approved assay with a 
lower limit of q uantification < 50 copies/mL (eg , < 40 copies/mL obtained by 
the Abbott real -time as say or < 20 copies/mL by the Ro che Taqman v2.0 
assay) performed by a laboratory that posses ses a CLIA certification or 
equivalent. Eligibility will be determined based on the screening value.  
 
After the screening visit, HIV -1 RNA quantification assay wi ll be performed at the 
protocol -designated laboratory. See the LPC for processing, ship ping, and 
storage information.  
 
6.3.1 8 Stored Plasma for HIV-1 RNA Single Copy Assay  (SCA)  
 
Plasma will be obtained and stored for determination of plasma HIV -1 RNA by 
SCA at the indicated visits per section 6.1 . This assay will be performed if 
significant  changes in the immunologic markers are observed  and/or if there are 
advances in the field that might provide further rationale for assessing the 
virologic endpoints in the absence of achieving the desired immunologic 
outcomes.  See the LPC for details on p rocessing plasma samples for the SCA 
test. 
 
6.3.1 9 Stored PBMC Reservoir Assays  
 
Samples will be collected  and stored as indicated in section 6.1  for potential  
comparative assessments of  change in HIV -1 reservoir size as measured by :  
a. Total and integrated HIV-1 DNA  
b. HIV-1 cell-associated RNA  
c. 2 LTR  circles  
 
Reservoir assays will be performed if significant changes in the immunologic 
markers are observed  and/or if there are advances in the field that might provide 
further rationale for assessing the virologic endpoints in the absence of achieving 
the desired immunologic outcomes .  
 
6.3.20  Stored Plasma/PBMC  
 
Stored Plasma/PBMC will be collected and stored as indicated in section 6.1 for 
future HIV-1 related studies and shipped according to the A5336 LPC.  
 
 6.3.21 Stored Oral Swabs Collection  
 
Oral swabs will be collected as indicated in section 6.1 to measure levels of 
HHV DNA. It is recommended that participants abstain from drinking coffee 
1 hour prior to collection. Samples will be stored and shipped accordin g to 
the A5336 LPC.  
 53 A5336  
FINAL  Version 2.0 
  05/21/15 
 
6.3.22 Plasma PK  Sample Collection  for Arm A Participant s 
 
Samples will be collected as indicated in section 6.1  for assessment of the PK  of 
ruxolit inib and ARV medicines . Apart from arriving at the clinic in a fasted state, 
participant s may eat and drink throughout the day as they wish. Each PK visit 
requires that the participant s take their morning dose of ruxolitinib and their 
ARV medications as  observed do ses administered in the clinic. Participant s 
should be contacted the night befo re and reminded not to take their morning  
dose of ruxolitinib or their ARV medications until instructed during their clinic visit, 
and to b ring their study and ARV medications (including EFV)  with them in the 
morning.  The timing of the previous drug admini stratio n must be documented. If 
participant  skipped pre vious day’s medication for the  week s 1 and 4  visits or 
took ruxolitinib before arriving at clinic , then baseline PK sampling should not be 
drawn and an alternative visit should be scheduled to measure PK. The exact 
time (hour and minute) of administration of the observed dose of ruxoli tinib and 
ARV must be recorded on the CRF , along with t he exact time at which each 
blood sample was obtained.  Samples will be collected at the following time points 
during  each visit:  
 
 
 
 
 
 
 
 
 
 
 
The use of an  intraven ous (IV) catheter is optional depending on participant  
preference.  Please refer to the LPC for sample collection, processing, storage 
and shipping information.  
 
6.3.23 Medication Diary  for Arm A Participant s  
 
At the weeks  before the PK assessment, a medication diary will be given to 
participant s and collected from participant s at the PK visits as indicated in 
section 6.1. Participant s will be instructed to record the date and time  they took  
their ruxolitinib and their ARV medications for the 3 days preceding the  PK study 
visit.  
 
6.3.24 Adherence  Assessment  
 
Self-reported adherence for ruxolitinib  and ARV will be performed at the indicated 
visits per section 6.1.   
 
 
 Hour  Activity  
-0.5 – 0.0 Pre-dose (baseline)  PK sample  
0.0 Obser ved Administration of study drug and 
ARV medications ; start clock; record 
administration time  
1.0 – 1.5 PK sample  
2.5 – 4.0 PK sample  
4.0 – 6.0 Lunch  
6.0 – 8.0 PK sample  
 54 A5336  
FINAL  Version 2.0 
  05/21/15 
 
7.0 CLINICAL MANAGEMENT  ISSUES  
 
7.1 Toxicity  
 
Only toxicitie s related to the study  drug , (ruxolitinib ,) will be considered in the toxicity 
management sectio n. The grading system is located in the Division of AIDS Table for 
Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), 
Version  2.0, November 2014 , located at the DAIDS R SC Web Site: http://rsc.tech -
res.com/safetyandpharmacovigilance/  
 
NOTE:  The study core team must be notified by e -mail regarding toxicities that result in a 
change in regimen  or discontinuation of study treatment  (actg.corea5336@fstrf.org ).   
 
7.1.1 Grade 1 or 2  
 
Participant s who develop a Grade 1 or 2 AE or toxicit y may continue study drug  
without al teration of the dosage, except as stated in sections 7.2.1 to 7.2.8 . For 
participant s experiencing Grade 1 or 2 AEs who choose to discontinue study 
drug, the site investigator should complete premature treatment discontinuation 
evaluations, and the partici pant  should be encouraged to complete evaluations 
off treatment/on  study . 
 
NOTE:   If participant s discontinue study drug  due to experiencing Grade 1 or 2 
AEs, this should be noted in the CRF as the reason for discontinuation.   
 
7.1.2 Grade 3  
 
Participant s who develop a Grade 3 AE thought to be related to the study drug 
should have their study medication  discontinued . If the investigator has 
evidence that the AE has NOT  been caused by study drug , study drug should 
be held until the AE or clinically signific ant laboratory ab normality is  Grade 
≤ 1 in severity , except as stated in s ections 7. 2.1 to 7.2.8  below.  
 
If the same Grade 3 AE  recurs at any time within 3 weeks  after restarting  
treatment, the study drug  must be permanently discontinued.  
 
Participant s experiencing Grade 3 AEs requiring pe rmanent dis continuation of 
study drug  should be followed weekly until resolution of the AE and should 
complete the premature treatment discontinuation evaluations  and should be 
encouraged to complete off treatment/on study evaluations.  
 
7.1.3 Grade 4  
 
Participant s who develop a Grade 4 symptomatic AE will have study drug  
permanently discontinued, except as stated in s ections  7.2.1 - 7.2.8 below . 
Participant s experiencing Grade 4 AEs requiring permanent discontinuation of 
study drug  should be followed weekl y until resolution of the AE and should 
complete the premature treatment discontinuation evaluations and the 
 55 A5336  
FINAL  Version 2.0 
  05/21/15 
 
participant  should be encouraged to complete off treatment/on study 
evaluations.  
 
7.2 Other Toxicities  
 
7.2.1 Platelet Count R eductions  
 
7.2.1.1 If a participant  develops a platelet count decrease  of >25% from 
baseline with an absolute value remaining above 200,000 /mm3, then 
dosing can continue.  
 
7.2.1.2 If the platelet count decreases from baseline by ≥ 25%, and the absolute 
value is between 150,000 -200,000 /mm3, then dosing of the study drug 
should be reduced to 10 mg QD. The CBC should then be repeated 
weekly until the platelet count either returns to >  200,000 /mm3 or 
remains less than 10% below the value that led to the dose reduction  for 
two consecutive values . If the platelet count returns > 200,000 /mm3, and 
is > 1.10 times the value that led to the dose reduction, then B ID study 
drug dosing can resume . The participant  will then have weekly 
monitorin g until t he platelet count remains  at a value that is greater than 
the value at BID dose resumption for at least two consecutive values . 
After resumption of the BID dosing if the platelet count decreases to <  
200,000/mm3, then the dose will be decreased to  10 mg daily and 
remain at that dose except as noted in section 7.2.3.   
 
7.2.1.3 If the platelet count decreases by ≥ 25%, and an absolute value below 
150,000/mm3, then the stud y drug should be discontinued. The CBC 
should then be repeated weekly until the  platelet count returns to >  
150,000 /mm3.   
 
7.2.2 Anemia/Neutropenia  
 
If a participant  experiences treatment -limiting  Grade 3 or higher decrease (in 
the opinion of the site investigator)  in anemia or neutropenia, then study  drug 
should be withheld. Anemia  should not be managed by transfusions or 
recombinant erythropoietin, and neutropenia should not  be managed with 
granulocyte -colony stimulating factor (G -CSF) or granulocyte -macrophage 
colony -stimulating factor (GM -CSF) . Once the anemia or neutropenia has 
returned t o Grade ≤  2, the study drug  can be restarted.  
 
7.2.3 Creatinine Clearance  
 
Any participant  experiencing a calculated CrCl <  60 mL/min should have the 
value confirmed within 7 days. For those participant s who experience a 
confirmed (2 consecutive)  CrCl < 60 mL/min, study drug should be withheld.  If 
the site investigator determines that another condition caused the d ecrease in 
CrCl, then study drug may be restarted if approved by the protocol team. 
Participant s should be followed as medically indica ted until the serum creatinine 
 56 A5336  
FINAL  Version 2.0 
  05/21/15 
 
returns to Grade ≤ 2 or baseline.   
 
7.2.4 Bruising  and Bleeding  
 
For participant s who report generalized bruising  and/or symptoms of 
unexplained or abnormal bleeding, hematoma or epistaxis , the study drug 
should be discontinued.  
 
7.2.5 Nausea (with or without vomiting) an d/or Diarrhea  
 
With the onset of Grade ≥  1 nausea  advise participant s to take study drug  with 
food. Participant s may also be treated as need ed with antiemetics given PO  or 
by suppository.  
 
In participant s with persistent nausea, consideration should be giv en for 
evaluation of pancreatitis, hepatitis, or hyperlactatemia/lactic acidosis, with 
evaluation for each if clinically indicated.  
 
For Grade 1 or 2 diarrhea, therapy should be continued with symptomatic 
treatment with antimotility agents. If Grade ≥  3 diarrhea occurs and is 
unresponsive to antimotility agents, and for which an alternative etiology (e.g., 
infectious diarrhea) is no t established  and judged related to study drug , study 
drug should be withheld  until resolution of diarrhea to G rade ≤ 1 or retu rn to 
baseline. If Grade ≥  3 diarrhea recurs upon the resumption of the stu dy drug, 
study drug  should be discontinued.   
 
7.2.6 Hypertriglyceridemia/Hyperlipidemia  
 
If elevated triglyceride or lipid levels are from a non -fasting blood draw, repeat 
the draw  after an 8 -hour fast. Only levels done in a fasting state should be used 
to determine toxicity management. Participant s with asymptomatic Grade  3 or 
higher increases in triglyceride, total cholesterol, or LDL ele vations must 
discontinue study drug. Please  see the recent review adapted from the original 
recommendations of the ACTG Cardiovascular Disease Focus Group 
(http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753589 ) for full discussion of  
management of hyperlipidemia in the context of HIV -1 disease.  
 
7.2.7  Hyperglycemia  
 
Participant s with Grade  3 or higher hyperglycemia must dis continue their 
study drug  unless judged unrelated to the study drug. If judged unrelated, 
study drug must be held  until the glucose abnormalities are Grade ≤ 1. Oral 
hypoglycemic and insulin should not be used in order to allow continued 
study drug administration.  A confirmatory fasting g lucose must be obtained 
within 2  weeks and prior to the institution of medical therapy.  
 
 
 
 57 A5336  
FINAL  Version 2.0 
  05/21/15 
 
7.2.8  AST or ALT Elevations  
 
Study drug must be discontinued for asymptomatic Grade  3 or higher AST/ALT 
elevations  unless judged unrelated to study drug . Careful assessments 
should be done to rule out the use of alcohol, non -study drug -related drug 
toxicity, or viral hepatitis as th e cau se of Grade 3 elevations. If judged 
unrelated, study drug  should be held until  AST and/or ALT levels are Grade ≤ 
1.  
 
7.3 Other Diseases  
 
For u nexplained confusion, seizures,  or other CNS  abnormality  site investigators should 
assess the participant , in conjunction with the primary physician to determ ine the cause 
of the symptoms. If no cause can be identified, or other  physician suspects PML, then 
study drug  should be discontinued. The participant  should then be followed on study 
until another  cause is established, or PML is considered confirmed or probable 
according to criteria in Appendix 100, ACTG Criteria for Clinic al and Other Events . For 
any infection, site investigators should assess the participant , in conjunction with the 
primary physician to determine relatedness to the study drug. If the infection is 
considered related to the study drug, then the study drug sh ould be discontinued.  
 
7.4 Pregnancy   
 
Female participant s who become pregnant  while on study treatment must immediately 
discontinue study treatment. Participant s should have the Premature Treatment/Study 
Discontinuation Evaluations completed within 2 weeks a fter stopping study treatment. 
Pregnancies that occur on study should be reported prospectively to The Antiretroviral 
Pregnancy Registry. More information is available at www.apregistry.com . Phone: 800 -
258-4263; F ax: 800 -800-1052.  
 
Participant s will be encouraged to remain in the study to be followed on study/off study 
treatment  until study completion and will be followed by telephone contact thereafter to 
determine the pregnancy outcome . If a participant  does not wish to remain on study 
follow -up at the time of study discontinuation, site staff should request permission to 
contact her regarding pregnancy and infancy outcomes at the end of the pregnancy. If 
the information is obtained, pregnancy outcomes for the participant  and infant will be 
submitted on a CRF at the end of pregnancy.  
 
7.5 Confirmed Virologic Failure  
 
In the event of confirmed virologic failure , defined as the occurrence of two sequential 
plasma HIV -1 RNA values  above the lower limit of quantification  in the absence of an 
interruption in ART , the study drug  must be stopped  for participants in Arm A . The 
participant  will be followed on study with all evaluation s perfo rmed through week 12. If 
the participant  does not agree to continue on study , then the premature study 
discontinuation evaluations should be completed.  
 
  
 58 A5336  
FINAL  Version 2.0 
  05/21/15 
 
8.0 CRITERIA FOR  DISCONTINUATION  
 
8.1 Premature  Treatment Discontinuation  
 
 Drug -related toxicity (see section 7. 1 Toxicity) . 
 Requirement for prohibited concomitant medications (see section  5.4). 
 Changes to or discontinuation of ART  for Arm A participants . 
 Participant  repeatedly noncompliant (missing greater than 3 do ses of study drug a 
week for 2  or more weeks ). 
 Confirmation of virologic failure  (see section 7.5).  
 Pregnancy or breast feeding . 
 Request by participant  to terminate treatment.  
 Clinical reasons believed life threatening by the physician, even if not addressed in 
the toxicity section  of the protocol . 
 
8.2 Premature Study Discontinuation  
 
 Failu re by the participant  to attend 2  consec utive clinic visits . 
 Request by the participant  to withdraw . 
 Request of the primary care provider if s/he thinks the study is no longer in the best 
interest of the participant . 
 Participant  judged by the investigator to be at significant risk of failing to comply with 
the provisions of the protocol as to cause harm to self or seriously interfere with the 
validity of the study results . 
 At the discretion of the I nstitutional Review Board /Ethics Committee  (IRB/EC) , FDA , 
NIAID, Office for Human Research Protecti ons (OHRP),  other government agenc ies 
as part of their duties, or the investigator.  
 
 
9.0 STATISTICAL CONSIDERATIONS   
 
9.1 General Design Issues  
 
A5336 is a randomized (2:1), prospective, open -label, 2-arm pilot clinical trial designed 
to assess the safet y and tolerability of ruxolitinib, and to evaluate whether 5 weeks of 
treatment with ruxolitinib decreases IL -6 levels in HIV -1 infected  participant s virally 
suppressed on ART. Participant s will be randomized 2:1 to receive ruxolitinib or  no 
study treatmen t. Participant s receiving ruxolitinib  will be followed on treatment for 5 
weeks, then for an additional 7 weeks off treatment, resulting i n a total 12 weeks of 
follow -up; participant s receiving no study treatment will be followed on -study for 12 
weeks.  The total sample size will be 60 participant s.  
 
 59 A5336  
FINAL  Version 2.0 
  05/21/15 
 
9.2 Objectives  
 
9.2.1  Primary Outcome Measures  
 
9.2.1.1  Safety  
 
Occurrence of any one of the following safety milestones (from entry to 
week 5) .  
 
 For participant s with entry CD4+ T  cell count <  700 cells/mm3, 
confirmed C D4+ decline >  33% of baseline and  to < 350 cells/mm3. 
 For participant s with entry CD4+ T cell count ≥  700 cells/mm3, a 
confirmed CD4+ T cell decline >  50 % of baseline.  
 Confirmed HIV -1 RNA level above  the lower limit of quantification 
in the absence of an interruption in ART . 
 New or recurrent CDC category C AIDS -indicator condition . 
 HIV-1 asso ciated infection including Varicella zoster . 
 Lymphoproliferative malignancies . 
 Discontinuation of ruxolitinib due to  thrombocytopenia . 
 Grade 4 or recurrence of Grade 3 anemia/neutropenia . 
 Any Grade 4 or recurrence of Grade 3 toxicity related to study drug . 
 New diagnosis of pneumonia, sepsis, or b acteremia . 
 
9.2.1.2  Tolerability  
 
 Occurrence of premature discontinuation of study treatment.  
 
9.2.1.3  IL-6 
 
Participant -specific change  in the level of plasma IL -6 (using geometric 
means of two ELISA measurements at pre -entry and entry, and weeks 4 
and 5 ).  
 
9.2.2  Secondary Objective Measures   
 
9.2.2.1  Proportion of participant s who experienced any one of the primary 
safety milestones during  total follow -up (from entry to week 12).  
 
9.2.2.2  Summary of safety laboratories at baseline and  weeks 1, 2, 4, 5, 10, and 
12. 
 
9.2.2.3  Change in the level of plasma IL-6 from baseline to weeks 4, 5, 10, and 
12.  
 
9.2.2.4  Changes in soluble markers of immune activation and inflammation in 
the peripheral blood (sCD14, TNF -α, IL-1α, IL-1β, mC SF, and neopterin) 
from baseline  to weeks 4, 5,  and 12 .   
 
 60 A5336  
FINAL  Version 2.0 
  05/21/15 
 
9.2.2.5  Changes in cellular markers  of immune activation and inflammation in 
the peripheral blood (HLA -DR, CD38, CD69 and CD1 4+/CD16 + 
monocyte levels) from baseline  to weeks 5 and 12 . 
 
9.2.2.6  Changes in plasma HIV -1 RNA and CD4+ T cell counts  from baseline  to 
weeks 2 , 5, and 12 . 
 
9.2.2.7  Changes in HIV -1 reservoir (HIV -1 RNA by SCA, cellular HIV-1 total 
RNA and DNA, 2 -LTRs, integrated DNA)  from baseline to weeks 5 and 
12.  
 
9.2.2.8  Level of HHV shedding (CMV, E BV, HHV 6, 7, 8) at pre -entry, entry, 
and weeks 1, 2, 4, 5, 10, and 12.  
 
9.2.3  Exploratory Objective Measures  
 
Summary measure of immune activation and inflammation and how changes in 
this measure differ between treatment groups.  
 
9.3 Randomization and Stratifi cation  
 
At study entry, participant s will be randomized at a 2:1 ratio (ruxolitinib: no study 
treatment ) using permuted blocks, without institutional balancing.  Participant s will be 
stratified based on whether they take EFV or do not take EFV at screening, in order to 
ensure balance by treatment arm for EFV.  
 
9.4 Sample Size and Accrual  
 
The sample size for A5336 was determined based on the primary endpoint for change in 
IL-6, while at the same time ensuring the sample size was feasible for an early phase 
investigation of the safety of ruxolitinib.  
 
9.4.1  Changes in IL -6 
 
A total sam ple size of 60 participant s will be  randomized at a 2:1 ratio to 
ruxolitini b:no study treatment , allowing for 20% lost  to follow -up and treatment 
discontinuation, is anticipated t o yield 48 evaluable participant s (see section 
9.6.1) . This will provide 80% power to de tect a treatment effect of 0.20 log 10 
pg/mL, that is a difference between treatment groups in  (change in plasma IL -6 
from entry to week 5), assuming that the standard d eviation (SD) of within -
participant  differences in IL -6 is 0.25 l og10 pg/mL , using a two -sided t -test at a 
0.10 alpha level.   
 
To minimize variability and maximize statistical power, at each key time point 
markers will be measured and analyzed as the aver age of samples taken 1 -2 
weeks apart (pre -entry and entry; at weeks 4 and 5; at weeks 10 and 12).  
 
 61 A5336  
FINAL  Version 2.0 
  05/21/15 
 
The treatment effect of 0.20 log 10 scale pg/mL  corresponds to a verage decreases 
of 37% and 0%  in plasma IL -6 levels in the ruxolitinib and no study treatmen t 
arms, respectively . This choice of effect size is based on prior data examining 
plasma IL -6 levels in HIV -1 infected populations and changes in IL -6 levels in 
ruxolitinib treated populations. Specifically, a 27% (95% confidence interval [ CI]: 
11% to 39%)  reduction in IL -6 levels after 4 weeks and a 37%  (95% CI: 13% to 
53%) reduction after 24 weeks of treatment was seen in  the Phase III 
COMFORT -1 study [3]. The effect size of 37% is selected because it is contained 
in the 95% CI for IL -6 reduction at 4 wee ks, and balances the interest in the 
efficacy endpoint with safety considerations as well as feasibility for this early 
phase investigation of the effects of the study treatment in the HIV -1 population.  
 
The assumed SD for within -participant  differences in  IL-6 of 0.25 log 10 is a 
pooled estimate  based on estimates of the  between -participant  SDs and within -
participant  correl ation from other ACTG studies. ACTG 5248 estimated the  
between -participant  SD of IL -6 at weeks 24 and 48 (after starting ART 
treatm ent); the SD was  0.335 at week 24 (based on 35 participant s) and 0.331 
at week 48 (based on 29 participant s). The SD estimate from 311 controls from 
NWCS 329 at week 48 was 0. 306 based on a single measure [ 71]. In addition, 
ACTG 5286 reported the within -partici pant  correlation between baseline and 
week 4 IL -6 measures to be 0.68 (n=43). Two versions of the pooled SD were 
calculated assuming the same SD at baseline and weeks 5, one assuming both 
SDs = 0.306, and the other assuming both SDs = 0.331. Each set of SD s was 
then pooled by accounting for the correlation between time points (r = 0.68), 
which resulted in SD=0.2448 and SD = 0.2648, respectively. The pooled 0.25 SD 
is the average of these values.  
 
9.4.2  Safety  
 
The total sample size of 60 participant s will be randomized at  a 2:1 ratio to 
ruxolitinib: no study treatment  ratio, results in 40 participant s receiving ruxolitinib 
and 20 receiving no study treatment . The 40 ruxolitinib -treated participant s will 
provide 90% probability of observing an AE that would o ccur in 6% or more of 
treated participant s. 
 
We assume the rate of events (outlined in 9.2.1.1) in the no study treatment arm 
will be no more than 2%. Assuming this rate in the no study treatment arm, we 
will have 80% power to detect a significant differen ce between the two arms, via 
a one-sided Fisher’s exact test with 5% alpha, if the rate in the ruxolit inib arm is 
27%.  
 
9.4.3  Accrual  
 
It is anticipated that participant s will accrue to the study at a rate of 7 -8 
participant s per month. At this rate, the study should fully accrue within 7 -9 
months after the first participant  enrolls.  
 
 
 62 A5336  
FINAL  Version 2.0 
  05/21/15 
 
9.5 Monitoring  
 
Accrual and summary of all Grade ≥ 2 signs and symptoms, laboratory abnormalities 
and diagnoses, and all reported AEs will be  reviewed by the team monthly. This 
summary will be pooled over the study arms. Baseline characteristics, early study 
treatment and study discontinuations, and virologic failures, pooled over study arms, will 
be reviewed r egularly by the protocol team. In addition, data and specimen avai lability 
will be also regularly reviewed.  The Statistical and Data Analysis Center (SDAC) will also 
prepare quarterly reports o f all Grade ≥ 2 events, and all reported AEs by stu dy arm, to 
be reviewed  by the DAIDS clinic al representative or designee.  
 
An ACTG -appointed Study Monitoring Committee (SMC) will review a ccrual, toxicity 
summaries, off-treatment and off -study rates, and  reasons broken down by study arms.   
An interim safety review by the SMC  is planned at the earliest of 6 participant s with 3 
weeks of follow -up, 2 participant s with Grade 3/4 toxicities, 3 participant s 
discontinuing study treatment due to toxicities, or 3 months after the first participant  
enrolls . Subsequent SMC reviews are planned at approximately 6 month intervals , or in 
the event of 2 participant s with Grade ≥ 3 toxicities or 3 participant s discontinuing 
study treatment due to toxicities in the interim.   
 
In the event the SMC review is triggered due to toxicities (2 participant s with 
Grade ≥ 3 toxicities or 3 participant s discontinuing study treatment due to 
toxicities), accrual will be paused while the SMC review takes place. In addition, 
during the course of the study if any participant  develops PML,  or neurologic 
condition  or dies of a drug -related adverse event , or if more than 2 participants, 
randomized to  Arm A, experience confirmed virologic failure (see section 7.5 for 
definition) then dosing for all study participants will be stopped.  
 
The team has requested the SMC consider the grade of the events, the time to 
resolution (if any ), the temporal relatio nship to drug administration,  and the site 
clinician’s judgment of the relationship to treatment. The team would recommend 
particular review by the SMC if there were high occurrences of the safety events 
described in section 9.2.1.1.   
 
Complementing the S MC reviews, the team will also notify the SMC of all drug 
related SAEs, Grade 4 toxicities, as well as all drug -related Grade 3 toxicities.   In 
addition, the core team or the SMC may ask for the SMC, at any time, to 
independently review all available safet y data (unblinded to treatment arms) and 
make a recommendation to the End-Organ Disease and Inflammation 
Transformative Science Group on whether to modify or stop the study. The team 
will also monitor (monthly) all Grade ≥ 2 signs and symptoms, laboratory 
abnormalities, and diagnoses, as well as all primary events with summaries 
pooled over study arms.  
 
9.6 Analyses  
 
9.6.1  Primary Analyses  
 
 63 A5336  
FINAL  Version 2.0 
  05/21/15 
 
As this is a pilot study of biologic activity, our primary analysis of efficacy will be 
an as -treated analysis, limit ed to participant s who meet all of the following 
conditions: (a) have data at baseline and week 5, (b)  for the ruxolitinib arm, 
remain on study treatment through week 5 and miss no more than 6 doses 
cumulatively, (c)  did not change ART, use prohibited medi cations, or have a 
virologic failure during this time period.  
 
Changes from baseline t o week 5 in plasma IL -6 (on log 10 scale) will be 
summarized with the mean and a 90% confidence interval (CI) for the mean 
change in each treatment arm, and compared betw een arms with a t-test. The 
baseline value will be calculated as the geometric mean of pre -entry and entry, 
and the week 5 value as the geometric mean of weeks 4 and 5.  If missing one of 
the pre -entry or entry values, then the available measure will be use d as the 
baseline value, and similarly, if missing one of the week 4 or week 5 values, then 
the available measure will be used as the week 5 value.  
 
Safety will be evaluated by estimating  the proportion of participant s in the 
ruxolitinib arm who experienc eing the primary safety outcome measure 9.2.1.1 . 
In addition, safety will be compared between the treatment arms via a one -
sided Fisher’s exact test at 5% alpha level , in terms of 9.2.1.1, but with this 
composite safety outcome modified to address the A5336  design where 
Arm B does not receive any study treatment . Specifically “discontinuation 
of ruxolitinib due to thrombocytopenia” will be modified to “occurrence of 
Grade 2 or higher thrombocytopenia” and “any Grade 4 or recurrence of 
Grade 3 toxicity relate d to study drug” will be modified to “any Grade 4 or 
recurrence of Grade 3 toxicity.” Tolerability will be evaluated by summarizing 
treatment modifications and discontinuations.  
 
9.6.2  Secondary Analyses  
 
Participant -specific c hanges from baseline to week  5 in other measurements of 
immune activation and inflammation, and CD4+ T -cell counts  will be summarized 
similarly to the primary efficacy measure, via means and 90% CIs for the mean 
change for each of the study arms.  The log 10 transformation is planned  for 
various solu ble and cellular markers. Comparisons between study arms will be 
done v ia the Wilcoxon rank sum test. HIV-1 RNA will be summarized by the 
number of participant s with confirmed HIV -1 RNA > 40 copies/mL and > 200 
copies /mL. Due to an anticipate d high proportion of lower limit of detection 
censoring, levels of HHV shedding will be compared between arms at week 
5 using a two -group Wilcoxon rank -sum test with 2 -sided alpha=0.10 level.  
Values below the lower limit of detection will be analyzed as t he lowest 
rank. In the event of limited lower limit of detection censoring, repeated 
measure modeling will be used to explore longitudinal changes in HHV 
shedding.  
 
Safety events (signs and symptoms, laboratory values, diagnoses, and other 
SAEs) will also be evaluated by summarizing the nature and rate  of AEs within 
 64 A5336  
FINAL  Version 2.0 
  05/21/15 
 
each study arm. Comparisons of overall and toxicity -specific grades between 
study arm s will be shown descriptively.  
 
Longitudinal changes from baseline to week 12 in all measures will be examin ed 
via descriptive summaries and plots.   
 
Statistical significance will be tested using a two -sided alpha = 0.10 with no 
adjustment for multiple testing.  
 
 
10.0 PHARMACOLOGY PLAN  
 
10.1 Pharmacology Objectives  
 
10.1.1  Primary Objective  
10.1.1.1  To measure the PK of ruxolitinib in this population of participant s with 
well-controlled HIV -1, and to  characterize the relationship  between 
ruxolitinib post-hoc estimated exposures (e.g., steady -state AUC = 
dose/CL/F) and immunol ogical biomarkers of the study drug.  
 
10.1.2  Secondary Objectives  
 
10.1.2.1  To compare ruxolitinib PK parameters in study participant s on specific 
ARV regimens to those reported for historical controls (no 
coadministered drugs) to assess the potential effect  of ARV 
administration on ruxolitin ib PK.  
 
 
10.1.2.2  To compare PK parameters of selected ARV medications  (NNRTI’s and 
INSTI’s) when co administered with ruxolitinib  to historical controls  (no 
coadministered drugs)  in order to explore possible effect s of rux olitinib 
on ARV concentrations.  
 
10.1.2.3 To evaluate the relationship between ruxolitinib concentrations in 
individual participant s with the time course of changes in biomarkers  
of immune response (hysteresis analysis).  
 
10.2 Pharmacology  Study Design  
 
Participant s randomized to  Arm A will undergo  blood sampling during two study visits 
as indicated in section 6.1 for asse ssment of the PK  of ruxolit inib and selected ARV  
drugs.  
 
Each PK visit req uires that the study participant  take their m orning dose of ruxolitinib as 
a timed observed do se administered in the clinic. During  each of  the two PK visits, four 
blood samples will be collected for PK analysis .  
 
 
 65 A5336  
FINAL  Version 2.0 
  05/21/15 
 
10.3 Primary and Secondary Data, Modeling, and Data Analysis  
 
The PK  of ruxolitinib following oral administration will be m odeled using population 
methods  with the NONMEM computer program (7.3  or later,  ICON Development 
Solutions, Leopardstown, Ireland ) [88], using the PLT Tools statistical interface ( 5.1 or 
later, PLT Soft, San Francisco, CA) . Resulting model parameters will be  compared t o a 
model recently reported for ruxolitinib  without co administered drugs  in patients with 
myelofibrosis  [89]. One and 2 -compartmental models, assuming first -order absorption 
into the plasma compartment will be fitted as they were reported to adequately des cribe 
ruxolitinib PK in the myelofibrosis population PK study. Between -participant  variances 
(IIV, 2) of PK parameters ( ) will be modeled as log -normally distributed, and an 
appropriate residual error model (e.g. , proportional and/or additive ,) will be used. Also, 
since PK samplings are  planned on two different o ccasions, we will also explore inter -
occasional variations in model parameters (e.g. , oral systemic clearance ( CL/F) and 
distribution volume (V/ F, where F=bioavailability, assumed=1, no IV dose a dministered) ), 
using established methods  [90]. Only concent rations >  LOQ were included in the 
analysis. Criteria for model convergence will include convergence to > 3 decimal places 
using an appropriate convergence method (e.g. , First Order Conditional Est imation with 
- interactions . Model diagnostics of goodness of fit will include the minimum value the 
NONMEM objective function (OFV= -2 log -likelihood), and visual inspection of graphics , 
e.g., correlation/symmetry of observations versus predictions (pop ulation and post -hoc), 
condi tional weighted residual  versus time and predictions  [91-93].  
 
Based on the planned 12 hour dosing regimen and reported ruxolitinib  plasma 
concentrations over a 12 hour  dose interval, we anticipate that a  1-compartment model 
will adequate ly describe the PK  of ruxolitinib in this study. However, if the  fit of the model 
to the data is improved using a 2 -compartment model, based upon the dispersion of 
residuals about the  respective lines of identity of observed versus predicted pla sma 
concentrations (population and post -hoc), and by a decrease in OFV, then  the 2 -
compartment model will be selected for further modeling.  We will also te st the 
significance of body -weight as possible continuous covariate on V/F and CL/F and 
creatinine cl earance (calculated using the Cockroft -Gault formula) as a covariate of CL/F 
[94]. The ability of the final model to simulate without bias will be tested using a “visual 
predictive check” method, in which >  1,000 individuals are simulated using the samplin g 
scheme (to ensure reproducible predictions), and used to compute 5% - 95% percentile 
ranges of concentration versus time. Actual data will then be  superimposed to visually 
assess model bias  [95]. Post -hoc fitted parameters from participant s administered 
ruxolitinib alone or with EFV will be compared using ANCOVA.  A value <  0.05 will be 
considered statistically significant for all tests. A similar model  will be attempted for EFV  
and other ARV s provided enough  participant s taking  a particular ARV  are recrui ted. 
Alternatively, their PK will be compared informally with published PK studies [ 50, 51, 96, 
97].  
 
Concen trations of ARVs  (NNRTI s and INSTI s) obtained at the same time as ruxolitinib  
concentrations will be compared to historical controls in order to ex plore the possible 
effect of ruxolitinib  on ARV concentrations. This is considered an exploratory analysis 
only.  
 
 66 A5336  
FINAL  Version 2.0 
  05/21/15 
 
10.4 Anticipated Outcomes  
 
Based on what is known about the clearance of ruxolitinib , NNR TIs, and INSTI s, we do 
not expect a clin ically signif icant effect of ruxolitinib  on ARV concentrations, nor a 
clinically significant effect of INSTI s on ruxolitinib concentrations. EFV  is a P450 enzyme  
inducer, and could decrease ruxolitinib  concentrations as a result, although the 
magnitude of this effect i s expected to be modest, and since concentrations of ruxolitinib  
would decrease rather than increase, this should not produce any safety  concerns for 
participant s. 
 
 
11.0 DATA COLLECTION AND MONITORING AND ADVERSE EVENT  REPORTING  
 
11.1 Records to Be Kept  
 
CRF will be provided for each participant . Participant s must not be identified by  name 
on any CRFs. Participant s will be identified by the patient identification number (PID) 
and study identification number (SID) provided by the ACTG DMC  upon randomization . 
 
11.2 Role of Data Manageme nt 
 
11.2.1 Instructions concerning the record ing of study data on CRFs will be provided by 
the ACTG DMC . Each CRS  is responsible for keying the dat a in a timely 
fashion . 
 
11.2.2  It is the responsibility of the ACTG DMC  to assur e the quality of computerized 
data for each ACTG study. This role extends from protocol development to 
generation of the final study databases.  
 
11.3 Clinical Site Monitoring and Record Availability  
 
11.3.1  Site monitors under contract to the NIAID will vi sit participating clinical research 
sites to review the individual participant  records, including consent forms, 
CRFs, supporting data, laboratory specimen records, and medical records 
(physicians’ progress notes, nurses’ notes, individuals’ hospital chart s), to 
ensure protection of study participant s, compliance with the protocol, and 
accuracy and completeness of records. The monitors also will inspect sites’ 
regulatory files to ensure that regulatory requirements are being followed and 
sites’ pharmacies t o review product storage and management.  
 
11.3.2  The site investigator will make study documents ( e.g., consent forms, drug 
distribution forms, CRFs) and pertinent hospital or clinic records readily 
available for inspection by the local IRB, the site monit ors, the FDA , the NIAID, 
the OHRP, and designee for confirmation of the study data.  
 
11.4 Expedited Adverse Event Reporting to DAIDS  
 
11.4.1  Adverse Event Reporting to DAIDS  
 67 A5336  
FINAL  Version 2.0 
  05/21/15 
 
Requirements, definitions and methods for expedit ed reporting of AEs  are 
outlined  in Version 2.0 of the DAIDS EAE Manual, which is available on the 
RSC website at    http://rsc.tech -res.com/safetyandpharmacovigilance/ . 
 
The DAIDS Adverse Events Reporting System  (DAERS ), an internet -based 
reporting system , must be used for expedited AE reporting to DAIDS.  In the 
event of system outages or technical difficulties, expedited AEs may be 
submitted via the DAIDS EAE Form. For  questions about DAERS,  please 
contact DAIDS -ES at  DAIDS -ESSupport@niaid.nih.gov . Site queries may also 
be sent  from within the DAERS application itself.  
Sites where DAERS has not been implemented will submit expedited AEs by 
documenting the information o n the current DAIDS EAE Form. This form is  
available on the R SC website: http://rsc.tech -
res.com/safetyandpharmacovigilance/ .  For questions about EAE reporting, 
please contact the R SC (DAIDSRSCSafetyOffice@tech -res.com ). 
 
11.4.2  Reporting Requirements for this Study  
 
 The SAE  Reporting Category, as defined in Version 2.0 of the DAIDS EAE 
Manual, will be used for this study.  
 The study agent  for which expedited reporting are  required is ruxolitinib.  
 In addition to the EAE Reporting Category identified above, other AEs that 
must be reported in an expedited manner are:  
o Platelet count decreases by ≥  25% from baseline  
o Platelet count with an absol ute value below 150,000 /mm3 
o New onset leukemia  
 
11.4.3  Grading Severity of Events  
 
The Division of AIDS Table for Grading the Severity of Adult and Pediatric 
Adverse Events (DAIDS AE Grading Table), Version  2.0, November 2014 , 
must be used and is available  on the DAIDS RSC Web site at http://rsc.tech -
res.com/safetyandpharmacovigilance/ . 
 
11.4.4  Expedited AE Reporting Period  
 
 The expedited AE reporting period for this study is as per the EAE  manual.  
 After the protocol -defined AE reporting period, unless otherwise noted, only 
suspected, unexpected serious adverse reactions ( SUSARs ), as defined in 
Version 2.0 of the EAE Manual , will be reported to DAIDS if the study staff 
become aware of the ev ents on a passive basis (from publicly available 
information).  
 
 
 68 A5336  
FINAL  Version 2.0 
  05/21/15 
 
12.0 PARTICIPANT S 
 
12.1 Institutional Review Board (IRB) Review and Informed Consent  
 
This protocol and the informed consent document (Appendix I) and any subsequent 
modifications will be rev iewed and approve d by the IRB or EC  responsible for oversight 
of the study. A signed consent form will be obtain ed from the participant  (or person with 
power of attorney for participant s who cannot consent for themselves ). The consent 
form will describe th e purpose of the study, the procedures to be followed, and the risks 
and benefits of participation. A copy of the consent form will b e given to the participant , 
or legal representative , and this fact will be documented in the participant ’s record.  
 
12.2 Participant  Confidentiality  
 
All laboratory specimens, evaluation forms, reports , and other records that leave the site 
will be identified by coded number only to maintain participant  confidentiality. All 
records will be kept locked. All computer entry and n etworking programs will be done 
with coded numbers only. Clinical information will not be released without written 
permission of the participant , except as necessary for monitoring by the ACTG, 
IRB/EC, FDA , NIAID, OHRP,  other government agencies  as part of  their duties  to 
ensure that research participant s are protected , or designee.   
 
12.3 Study Discontinuation  
 
The study may b e discontinued at any time by the ACTG, IRB/EC, FDA,  NIAID, OHRP, 
or government  agencies as part of their duties to ensure that rese arch participant s are 
protected.  
 
 
13.0 PUBLICATION OF RESEARCH FINDINGS  
 
Publication of the results of this trial will be governed by ACTG policies. Any 
presentation, abstract, or manuscript will be made available for review by the industry  
supporter (s) prior to submission .  
 
 
14.0 BIOHAZARD CONTAINMENT  
 
As the transmission of HIV and other blood -borne pathogens can occur through contact 
with contaminated needles, blood, and blood products, appropriate blood and secretion 
precautions will be employed by a ll personnel in the drawing of blood and shipping and 
handling of all specimens for this study, as currently recommended by the Centers for 
Disease Control and Prevention and the National Institutes of Health.  
 
All dangerous goods and materials, including diagnostic specimens and infectious 
substances, must be transported using packaging mandated by CFR 42 Part 72. Please 
refer to instructions detailed in the International Air Transport Association (IATA) 
Dangerous Goods Regulations.   
 69 A5336  
FINAL  Version 2.0 
  05/21/15 
  15.0 REFERENCES  
1. Hunt PW, Cao HL, Muzoora C, et al. Impact of CDD8+ T -cell activation on CD4+ T -cell 
recovery and mortality in HIV -infected Ugandans initiating antiretroviral therapy. AIDS. 
2011 Nov 13;25(17):2123 -31. 
2. Verstovsek S, Kantarjian H, Mesa RA, et al. Safety and  efficacy of INCB018424, a JAK1 
and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117 -27. 
3. Verstovsek S, Mesa RA, Gotlib J, et al. A double -blind, placebo -controlled trial of 
ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799 -807. 
4. Kohler JJ, Tuttle DL, Coberley CR, et al. Human immunodeficiency virus type 1 (HIV -1) 
induces activation of multiple STATs in CD4+ cells of lymphocyte or 
monocyte/macrophage lineages. J Leukoc Biol. 2003;73:407 -16. 
5. Chomont N, El -Far M, Ancuta P, et al. H IV reservoir size and persistence are driven by T 
cell survival and homeostatic proliferation. Nat Med. 2009;15:893 -900. 
6. Chun TW1, Engel D, Mizell SB, et al. Induction of HIV -1 replicatoion in latently infected 
CD4+ T cells using a combination of cytoki nes. J Exp Med. 1998 Jul 6;188(1):83 -91.  
7. Interleukin -6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium, 
Hingorani AD, Casas JP. The interleukin -6 receptor as a target for prevention of 
coronary heart disease: a mendelian randomization an alysis. Lancet. 2012 Mar 
31;379(9822):1214 -24. 
8.. Borges A, Silverberg MJ, Wentworth D, et al. Predicting risk of cancer during HIV 
infection: the role of inflammatory and coagulation biomarkers. Clin Science. 2013; 
27(9):1433 -1441.   
9. Baker J, Huppler HK, Sing A, et al, CDC SUN Study Investigators. Monocyte activation, 
but not T cell activation, predicts progression of coronary artery calcium in a 
contemporary HIV cohort. 20th Conference on Retroviruses and Opportunistic 
Infections, March 3 -6, 2013. Atl anta, GA, USA.    
10. Gavegnano C, Detorio Ma, Schinazi RF, et al. Cellular pharmacology and potency of 
HIV-1 nucleoside analogs in primary human macrophages. Antimicrob Agents 
Chemother. 2013 Mar;57(3):1262 -9. 
11. Chomont N, El -Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T 
cell survival and homeostatic proliferation. Nat Med. 2009 Aug;15(8):893 -900. 
12. Besson  GJ, Lalama CM, Bosch RJ, et al. HIV -1 DNA decay dynamics in blood during  
more than a decade of suppressive antiretrovi ral therapy. Clin Infect Dis. 2014 Nov  
1;59(9):1312 -21. 
13. Cobos -Jimenez V, Booiman T, Hamann J, et al. Macrophages and HIV -1. Curr Opin HIV 
AIDS. 2011;6:385 -90. 
 70 A5336  
FINAL  Version 2.0 
REFERENCES (Cont'd)   05/21/15 
 
14. Trono D, Van Lint C, Rouzioux C, et al. HIV persistence and the prospect of long -term 
drug-free remissions for HIV -infected individuals. Science. 2010;329:174 -80. 
15. Rivera -Rivera L, Perez -Laspiur J, Colon K, et al. Inhibition of interferon response by 
cystatin B: implication in HIV replication of macrophage reservoirs. J Neurovirol. 
2012;18 :20-29. 
16. McArthur JC, Steiner J, Sacktor N, et al. Human immunodeficiency virus -associated 
neurocognitive disorders: Mind the gap. Ann Neurol. 2010;67:699 -714. 
17. Anthony IC, Ramage SN, Carnie FW, et al. Influence of HAART on HIV -related CNS 
disease an d neuroinflammation. J Neuropathol Exp Neurol. 2005;64:529 -536. 
18. Bachis A, Avdoshina V, Zecca L, et al. Human immunodeficiency virus type 1 alters 
brain -derived neurotrophic factor processing in neurons. J Neurosci. 2012;32:9477 -84. 
19. Mocchetti I, Bac his A, Avdoshina V. Neurotoxicity of human immunodeficiency virus -1: 
viral proteins and axonal transport. Neurotox Res. 2012;21:79 -89. 
20. Dunfee R, Thomas ER, Gorry PR, et al. Mechanisms of HIV -1 neurotropism. Curr HIV 
Res. 2006;4:267 -78. 
21. Fischer -Smith T, Bell C, Croul S, et al. Monocyte/macrophage trafficking in acquired 
immunodeficiency syndrome encephalitis: lessons from human and nonhuman primate 
studies. J Neurovirol. 2008;14:318 -26. 
22. Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV -1 and their role in viral 
persistence. Curr HIV Res. 2008;6:388 -400. 
23. Gavegnano C, Schinazi RF. Antiretroviral therapy in macrophages: implication for HIV 
eradication. Antivir Chem Chemother. 2009;20:63 -78. 
24. Herbein G, Varin A. The macrophage in HIV -1 infection: from activation to deactivation? 
Retrovirology. 2010;7:33.  
25. Poli G, Bressler P, Kinter A, et al. Interleukin 6 induces human immunodeficiency virus 
expression in infected monocytic cells alone and in synergy with tumor necrosis factor 
alpha by transcriptional and post -transcriptional mechanisms. J Exp Med. 1990;172:151 -
58. 
26. Wahl SM, Greenwell -Wild T, Peng G, et al. Viral and host cofactors facilitate HIV -1 
replication in macrophages. J Leukoc Biol. 2003;74:726 -35. 
27. Albini A, Benelli R, Giu nciuglio D, et al. Identification of a novel domain of HIV that 
involved in monocyte chemotaxis. J Biol Chem. 1998;273:15895 -15900.  
28. Fantuzzi L, Conti L, Gauzzi MC, et al. Regulation of chemokine/cytokine network during 
in vitro differentiation and HIV -1 infection of human monocytes: possible importance in 
the pathogenesis of AIDS. J Leukoc Biol. 2000;68:391 -99. 
 71 A5336  
FINAL  Version 2.0 
REFERENCES (Cont'd)   05/21/15 
 
29. Koziel H, Eichbaum Q, Kruskal BA, et al. Reduced binding and phagocytosis of 
Pneumocystis carinii by alveolar macrophages from persons infec ted with HIV -1 
correlates with mannose receptor downregulation. J Clin Invest. 1998;102:1332 -44. 
30. Reardon CC, Kim SJ, Wagner RP, et al. Phagocytosis and growth inhibition of 
Cryptococcus neoformans by human alveolar macrophages: effects of HIV -1 infecti on. 
AIDS. 1996;10:613 -18. 
31. Macatonia SE, Gompels M, Pinching AJ, et al. Antigen -presentation by macrophages 
but not by dendritic cells in human immunodeficiency virus (HIV) infection. Immunology. 
1992;75:576 -81. 
32. Cory TJ, Schacker TW, Stevenson M, et  al. Overcoming pharmacologic sanctuaries. 
Curr Opin HIV AIDS. 2013 May;8(3): 190 -5. 
33. Buzon MJ, Massanella M, Llibre JM, et al. HIC -1 replication and immune dynamics are 
affected by raltegravir intensification of HAART -suppressed participant s. Nat Med. 
2010;16(4):460 -65. 
34. Hatano H, Strain MC, Scherzer R, et al. Increase in 2 -long terminal repeat circles and 
decrease in D -dimer after raltegravir intensification in patients with treated HIV infection: 
A randomized, placebo -controlled Trial. J Infect Dis . 2013;208(9):1436 -42. 
35. Williams DW, Eugenin EA. Calderon TM, et al. Monocyte maturation, HIV susceptibility, 
and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. J 
Leukoc Biol. 2012 Mar;91(3):401 -15. 
36. Buckner CM, Calderon TM, Williams DW, et al. Characterization of monocyte 
maturation/differentiation that facilitates their transmigration across the blood -brain 
barrier and infection by HIV: Implications for NeuroAIDS. Cell Immunol. 
2011;267(2):109 -23. 
37. Fischer -Smith T, Croul S, Sverstiuk AE, et al. CNS invasion by CD14+/CD16+ peripheral 
blood -derived monocytes in HIV -dementia: perivascular accumulation and reservoir of 
HIV infection. J Neurovirol. 2001 Dec;7(60:528 -41. 
38. Valcour VG, Shiramizu BT, Shikuma CM. HIV  DNA in circulating monocytes as a 
mechanism to dementia and other HIV complications. J Leukoc Biol. 2010 
Apr;87(4):621 -6. 
39. Ganau M, Prisco L, Pescador D, et al. Challenging new targets for CNS -HIV infection. 
Front Neurol. 2012;3:43.  
40. Chugh P, Fan S,  Planelles V, et al. Infection of human immunodeficiency virus and 
intracellular viral Tat protein exert a pro -survival effect in a human microglial cell line. J 
Mol Biol. 2007;366:67 -81. 
41. Eggers C, Hertogs K, Sturenburg HJ, et al. Delayed central nervo us system virus 
suppression during highly active antiretroviral therapy is associated with HIV 
encephalopathy, but not with viral drug resistance or poor central nervous system drug 
penetration. AIDS. 2003;17:1897 -1906.  
 72 A5336  
FINAL  Version 2.0 
REFERENCES (Cont'd)   05/21/15 
 
42. Kaul M, Zheng J, Okamoto S, et a l. HIV -1 infection and AIDS: consequences for the 
central nervous system. Cell Death Differ. 2005;12 Suppl 1:878 -92. 
43. Kazmierczak K, Potash MJ. Host and virus strain dependence in activation of human 
macrophages by human immunodeficiency virus type 1. J  Neurovirol. 2007;13:452 -61. 
44. Rumbaugh JA, Nath A. Developments in HIV neuropathogenesis. Curr Pharm Des 
2006;12:1023 -44. 
45. Yilmaz A, Price RW, Gisslen M. Antiretroviral drug treatment of CNS HIV -1 infection. J 
Antimicrob Chemother. 2012;67:299 -311. 
46. Sandler NG, Douek Daniel C. Microbial translocation in HIV infection: causes, 
consequences and treatment opportunities. Nat Rev Microbiol. 2012 Sep;10: 655 -66. 
47. Shuai Ke, Liu Bin. Regulation of JAK/STAT signaling in the immune system, Nature 
Reviews Immunology. 2003 Nov;3:900 -11. 
48. Deisseroth A, Kaminskas E, Grillo J, et al. U.S. Food and drug administration approval: 
ruxolitinib for the treatment of patients with intermediate and high -risk myelofibrosis. Clin 
Cancer Res. 2012;18:3212 -17. 
49. Gavegn ano, C, Detorio, M, Montero, C, et al. Ruxolitinib and tofacitinib are potent 
and selective inhibitors of HIV -1 replication and virus reactivation in vitro. Antimicrob 
Agents Chemother.2014; 58:1977 -1986.  
50. Shi JG, Chen X, McGee RF, et al. The pharmacokin etics, pharmacodynamics, and 
safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 
2011;51:1644 -54. 
51. Verstovsek S, Kantarjian HM, Estrov Z, et al. Long -term outcomes of 107 patients with 
myelofibrosis receiving JAK1/JAK2 i nhibitor ruxolitinib: survival advantage in comparison 
to matched historical controls. Blood. 2012;120:1202 -09. 
52. Shi JG, Chen X, Emm T, et al. The effect of CYP3A4 inhibition or induction on the 
pharmacokinetics and pharmacodynamics of orally administer ed ruxolitinib 
(INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol. 2012;52:809 -818. 
53. Tam CS, Verstovsek S. Investigational Janus kinase inhibitors. Expert Opin Invest 
Drugs. 2013;22(6):687 -99.   
54. Jung CW, Shih LY, Ziao Z. Efficacy and saf ety of ruxolitinib in Asian patients with 
myelofibrosis. Leuk Lymphoma. 2014 Nov 20:1 -8. 
 
55. Tefferi A, Litzow MR, Pardanani A. Long -term outcome of treatment with ruxolitinib in  
  myelofibrosis.  N Engl J Med. 2011 Oct 13;365(15):1455 -57. 
 
56. Wathes R, Moule S, Milojkovic D.  Progressive multifocal leukoencephalopathy  
 associated with ruxolitinib. N Engl J Med. 2013 Jul 11;369(2):197 -8. 
 
 73 A5336  
FINAL  Version 2.0 
REFERENCES (Cont'd)   05/21/15 
 
57. Chen YH, Lee CH, Pei SN. Pulmonary tuberculosis reactivation following  
ruxolitinib treatment in a patient with pr imary myelofibrosis. Leuk Lymphoma. 2014 Nov 
5:1-2. 
 
58. Palandri F, Polverilli N, Catani L, et al. Ruxolitinib -associated tuberculosis: a case  
 of successful ruxolitinib rechallenge. Ann Hematol. 2014 Aug 30.  
 
59. Hopman RK, Lawrence SJ, Oh ST. Dissemina ted tuberculosis associated with  
 ruxolitinib. Leukemia. 2014 Aug;28(8):1750 -1. 
 
60. Colomba C, Rubino R, Siracusa L, et al. Disseminated tuberculosis in a patient  
treated with a JAK2 selective inhibitor: a case report. BMC Res Notes. 2012 Oct 5;5:552.  
 
61. Caocci G, Murgia F, Podda L, et al. Reactivation of hepatitis B virus infection  
following ruxolitinib treatment in a patient with myelofibrosis. Leukemia. 2014 
Jan;28(1):225 -7. 
 
62. Shen CH, Hwang CE, Chen YY, et al. Hepatitis B virus reactivation ass ociated with  
 ruxolitinib. Ann Hematol. 2014 Jun;93(6):1075 -6. 
 
63. Tong LX, Jackson J, Kerstetter J, et al. Reactivation of herpes simplex virus  
infection in a patient undergoing ruxolitinib treatment. J Am Acad Dermatol. 2014 
Mar;70(3):e59 -60. 
 
64. Lee  SC, Feenstra J, Georghiou PR. Pneumocystis jiroveci pneumonitis  
 complicating ruxolitinib therapy. BMJ Case Rep. 2014 Jun 2;2014.  
 
65. Goldberg RA, Reichel E, Oshry LJ. Bilateral toxoplasmosis retinitis associated  
 with ruxolitinib. N Engl J Med. 2013 A ug 15;369(7):681 -3. 
 
66. Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with  
 ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest. 2013 May;143(5):1478 -9. 
67. Verstovsek, S, Gotlib, J, Gupta, V, et al. Management of cytopenias in patients with 
myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy 
outcomes. OncoTargets and Therapy. 2014;7:13 –21. 
68. Ward BA, Gorski JC, Jones DR, et al. The cytochrome P450 2B6 (CYP2B6) is the main 
catalyst of efaviren z primary and secondary metabolism: implication for HIV/AIDS 
therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J 
Pharmacol Exp Ther. 2003;306:287 -300. 
69. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation  biomarkers and 
mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203.  
70. Duprez DA, Neuhaus J, Kuller LH, et al. Inflammation, coagulation and cardiovascular 
disease in HIV -infected individuals. PloS one. 2012;7(9):e44454.  
71. Tenorio, A, Z heng Y, Bosch RJ, et al. Soluble markers of inflammation & coagulation, 
but not T -Cell activation, predict non -AIDS -defining events during suppressive 
 74 A5336  
FINAL  Version 2.0 
REFERENCES (Cont'd)   05/21/15 
 
antiretroviral therapy (Abstract #790). 20th Conference on Retroviruses and 
Opportunistic Infections, 201 3. Atlanta, GA.  
72. Hunt PW, Cao HL, Muzoora C, et al. Impact of tryptophan catabolism on CD4+ T Cell 
recovery and mortality in HIV -infected Ugandans initiating antiretroviral therapy (Abstract 
# MOAA0105). 6th International AIDS Society Conference on HIV Pathogenesis, 
Treatment, and Prevention. July 17 -20, 2011. Rome, Italy.  
73. Neuhaus, J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and 
renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201(12):1788 -
95. 
74. Justice, AC, Freiberg MS, Tracy R, et al. Does an index composed of clinical data reflect 
effects of inflammation, coagulation, and monocyte activation on mortality among those 
aging with HIV? Clin Infect Dis. 2012;54(7):984 -94. 
75. Lederman MM, Calabre se L, Funderburg NT, et al. Immunologic failure despite 
suppressive antiretroviral therapy is related to activation and turnover of memory CD4 
cells. J Infect Dis. 2011;204(8):1217 -26. 
76. Bjerk, SM, Baker JV, Emery S, et al. Biomarkers and bacterial pneum onia risk in 
patients with treated HIV infection: a case -control study. PloS one. 2013;8(2):e56249.  
 
77. Ledwaba, L, Tavel JA, Khabo P, et al. Pre -ART levels of inflammation and coagulation 
markers are strong predictors of death in a South African cohort w ith advanced HIV 
disease. PloS one. 2012;7(3):e24243.  
 
78. Hamlyn E, Fidler S, Stohr W, et al. Interleukin -6 and D -dimer levels at seroconversion as 
predictors of HIV -1 disease pregression. AIDS. 2014 Mar 27;28(6):869 -74. 
 
79. Della Chiara G, Crotti A, Lib oi E, et al. Negative regulation of HIV -1 transcription by a 
heterodimeric NF -kappaB1/p50 and C -terminally truncated STAT5 complex. J Mol Biol. 
2011;410:933 -943. 
 
80. Lassen K, Han Y, Zhou Y, et al. The multifactorial nature of HIV -1 latency. Trends Mol 
Med. 2004;10:525 -53. 
 
81. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during 
chronic HIV infection. Immunity. 2013 Oct 17;39(4):633 -45. 
 
82. Ho YC, Shan L, Hosmane NN, et al. Replication -competent noninduced proviruses in 
the late nt reservoir increase barrier to HIV -1 cure. Cell. 2013 Oct 24;155(3):540 -51. 
 
83. Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with 
ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest 2013; 143(5): 1478 -9. 
 
84. Tong LX, Jacks on J, Kerstetter J, Worswick SD. Reactivation of herpes simplex  
 virus infection in a patient undergoing ruxolitinib treatment. JAAD ONLINE 2014.  
 
 75 A5336  
FINAL  Version 2.0 
REFERENCES (Cont'd)   05/21/15 
 
85. Gianella S, Massanella M, Richman DD, et al. Cytomegalovirus replication in  
semen is  associated with higher levels of proviral HIV DNA and CD4+ T cell 
activation during antiretroviral treatment. J Virol 2014; 88(14): 7818 -27. 
 
86. Gianella S, Strain MC, Rought SE, et al. Associations between virologic and  
immunologic dynamics in blood and in the male genit al tract. J Virol 2012; 86(3): 
1307 -15. 
 
87. Gianella S , Massanella M, Wertheim JO, et al.  The Sordid affair between human 
herpesvirus and human immunodeficiency virus. J Infect Dis. 2015 Mar 6. pii: 
jiv148. [Epub ahead of print] Review.  
88. Beal S, Sheine r LB, Boekmann A, et al. NONMEM's User's Guides. ICON Development 
Solutions, Ellicott City, MD, USA, 2009.  
89. Chen X1, Williams WV, Sandor V, et al. Population pharmacokinetic analysis of orally -
administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis 
(PMF), post -polycythemia vera myelofibrosis (PPV -MF) or post -essential 
thrombocythemia myelofibrosis (PET MF). J Clin Pharmacol. 2013 Jul;53(7):721 -30. 
90. Karlsson MO, Sheiner LB.The importance of modeling interoccasion variabil ity in 
population pharmacokinetic analyses. J Pharmacokinet Biopharm. 1993 Dec;21(6):735 -
50. 
91. Hooker A, Staatz CE, Karlsson MO. Conditional weighted residuals, an improved model 
diagnostic for the FO/FOCE methods. Annual Meeting of the Population Approa ch 
Group in Europe, 2012, Venice, Italy. Abstract #1001.  
92. Hooker AC, Staatz C, Karlsson MO. Conditional weighted residuals (CWRES): a model 
diagnostic for the FOCE method. Pharm Res. 2007;24:2187 -97. 
93. Karlsson MO, Savic R. Diagnosing Model Diagnostic s Pharmacology & Therapeutics. 
2007;82:17 -20. 
94. Wurtz R, Itokazu G, Rodvolt K. Antibiotic dosing in obese patients. Clin Infect Dis. 
1997;25:112 -8. 
95. Bergstrand M, Hooker AC, Wallin JE, et al. Prediction -corrected visual predictive checks 
for diagnosin g nonlinear mixed -effects models. AAPS J. 2011 Jun;13(2):143 -51.  
96. Kakuda T, Sekar V, Vis P, et al. Pharmacokinetics and pharmacodynamics of darunavir 
and etravirine in HIV -1-infected, treatment -experienced patients in the gender, race, and 
clinical exp erience (GRACE) trial. AIDS Res Treat. 2012:186987.  
97. Abdelhady AM, Desta Z, Jiang F, et al. Population pharmacogenetic -based 
pharmacokinetic modeling of efavirenz, 7 -hydroxy - and 8 -hydroxyefavirenz. J Clin 
Pharmacol. 2014 Jan;54(1):87 -96. 
   A5336 ( 05/21/15) 
FINAL  Version 2.0 
  Page 1 of 10 
  APPENDIX I  
 
DIVISION OF AIDS  
AIDS CLINICAL TRIALS GROUP (ACTG)  
SAMPLE INFORMED CONSENT   
 
For protocol A5336:  A Randomized, Pilot Study of Ruxolit inib in Antiretroviral -Treated HIV -
Infected Adults  
 
SHORT TITLE FOR THE STUDY: (A5336) Trial of Ruxolitinib in Antiretrovir al-Treated HIV -
Infected Adults ( FINAL  Version 2.0, Dated 05/21/15)  
 
 
INTRODUCTION  
 
When a person becomes infected with HIV (the virus that causes AIDS), his/her immune system 
(the system that helps fight infection) is weakened (partly because the number o f CD4+ cells 
[the number of white blood cells that fight infection ] goes down). Despite successful treatment 
with antiretroviral therapy (ART), latent reservoirs (infected cells that are not actively producing 
HIV) remain present in the blood and contribut e to ongoing immune system activation (immune 
system  becomes active  in response to an infection ) and  inflammation (reaction to an infection or 
irritation) in the body.  
 
You are being asked to take part in this research study because you:  
 
 are infected with  HIV-1 
 have a very low viral load  (amount of virus in the blood)  
 have CD4+ T cell count  of more than 350 cells  
 are on stable ART for at least 3  months  
 
This study is sponsored by the National Ins titutes of Health (NIH) for  the AIDS Clinical Trials 
Group (A CTG). The doctor in charge of this study at this site is: ( insert name of Principal 
Investigator ). Before you decide if you want to be a part of this study, we want you to know 
about the study.  
 
This is a consent form. It gives you information about this study. The study staff will talk with you 
about this information. You are free to ask questions about this study at any time.  If you agree 
to take part in this study, you will be asked to sign this consent form. You will get a copy to 
keep.  
 
 
WHY IS THIS STUDY BEING DONE?  
 
The purpose of this study is to find out more about the safety and tolerability  (how well your 
body accepts the study drug ) of the u se of ruxolitinib in persons  with HIV -1 infection who are 
also being treated with ART. We want to learn w hether ruxolitinib will decrease inflammation 
and immune activation  in the body; whether ruxolitinib will change the level of HIV -1 in your 
blood; and how ruxolitinib interacts with ART in the blood.  
   A5336 ( 05/21/15) 
FINAL  Version 2.0 
 APPENDIX I (Cont'd)  Page 2 of 10 
 
Ruxolitinib is approved by the U.S. Food and Drug Admin istration (FDA)  to treat myelofibrosis, a 
disorder in which bone marrow is replaced by scar (fibrosis) tissue. Many of the cytokines 
(regulators of the body’s reaction to infection, immune response, and inflammation) affected by 
myelofibr osis are also affe cted by HIV. Because ruxolitinib acts on these cytokines, it is 
proposed that it may also be a possible treatment for HIV  by reducing inflammation. 
Inflammation has been associated with organ disease in people living with HIV.  
 
 
WHAT DO I HAVE TO DO IF I A M IN THIS STUDY?  
 
If you decide to take part in this research study, you will be asked to sign this consent form and 
schedule  a screening visit to determine if you can join the study . If so, you will be randomly 
assigned (as if by the toss of a coin) to either one of the two groups, Group A or Group B 
(see below) . The screening visit will take about 1.5 hours.   
 
Screening visit  
 Your HIV -1 infection will be confirmed. If there is no record available, you will have another 
HIV-1 test. You may have to sign a s eparate consent form before having this test.  
 You will have a physical exam and will be asked about your health and medicines you have 
taken in the past or are taking now.  
 You will have about 1 tablespoon  of blood drawn for routine safety blood tests and  to 
measure HIV -1 viral load . You will be given the test results when they are available.  
 If you are a woman able to become pregnant, you will be asked to give a urine or blood 
sample to see if you are pregnant. You will not be able to enroll in this study i f you are 
pregnant. You will be told the result of the test when it becomes available.   
 
If you do not enroll into the study  
If you decide not to take part in this study or if you do not meet the eligibility requirements, we 
will still use some of your in formation. As part of this screeni ng visit, some demographic (for 
example , age, sex, race), clin ical (for example , disease condition, diagnosis), and laboratory (for 
example , CD4+ T  cell count, viral load) information is being collected from you so that AC TG 
researchers may help determine whether there are patterns or common reasons why people do 
not join a study.  
 
Pre-Entry  
If you qualify for the study, you will come to the clinic at least one day after the screening visit 
for the pre -entry visit. Please n ote it is possible that the pre -entry and screening visits may be 
combined. If not, at the pre -entry visit you will have a complete physical exam. You will also 
have blood drawn for CD4+ T cell count and for samples to be stored for future HIV -related 
testing for this study. A total of 2 tablespoon  of blood will be drawn at this visit. Saliva and cells 
from your cheeks will be collected with an oral swab and tested for the presence of 
human herpes  viruses  (HHV; a virus causing sores most often found around the mouth 
or the genitals) . The visit will last about 30 -60 minutes.  
 
Entry visit  
If you are eligible for the study, you will come in for an entry visit. You will need to fast before 
your entry visit. Fasting means nothing to eat or drink other than water  and medication for 8 
hours before your visi t. The visit will last about 60-90 minutes.  
   A5336 ( 05/21/15) 
FINAL  Version 2.0 
 APPENDIX I (Cont'd)  Page 3 of 10 
 
During this visit:  
 You will have a physical exam performed. You will be asked about medical history and any 
medicines you have taken since the last visit.   
 If you are  a woman able to get pregnant, you will be asked to provide blood or urine for a 
pregnancy test. You cannot start treatment if you are pregnant. You will be given the results 
of your pregnancy test as soon as it becomes available.  
 You will have 7 tablespoo ns of blood drawn for routine safety blood tests  including lipid 
testing , CD4+ T cell count, viral loa d, immune tests  along with other tests. In addition, some 
of your blood will  be stored for future testing required by the study.  
 Saliva and cells from you r cheeks will be collected with an oral swab and tested for 
the presence of HHV . 
 You will be asked ques tions about adherence to antiretroviral (ARV) medicines.  
 If you are in Group A, y ou will be given a medication diary to record the d ate and time of 
ruxolitinib, and ARV  medicines for the 3 days preceding the week 1 study visit.  The 
medication diary will be collected at the week 1 study visit.  
 
Once all these tests are done, you will be randomly assigned to either one of the two groups 
(Group A or Group B) . However, because of the way the study is designed, there will be a 
greater chance of your being in Group A.  
 
 Group A: Takes ruxolitinib by mouth t wice a day for the next 5 weeks . 
 Group B:  No study treatment .   
 
If you are randomized to Group A, at this visit study staff will give you enough study drug  to last 
until the next study visit. You will be asked not to drink grapefruit juice or eat grapefruit while 
taking the study drug. At the week 5 visit, you must return any remaining study drug.   
 
On Study Visits a fter Entry  
Regardless of which group you are assigned to, y ou will come to the clinic  one week  after your 
initial entry v isit (week 1) and then study weeks 2, 4, 5 . For the week 5 visit, you will be asked to 
fast, which means that for eigh t hours before your vis it, you cannot eat or drink anything except 
water and your medication. Your next visit w ill not be until week 10 on study  and your f inal visit 
will be at week 12 . Visits will take about 30 -60 minutes  except weeks 1 and 4 study visits  if you 
are in Group A (see 5th bullet below) . If you are in Group A, a t the week 2 study visit you will be 
given a medication diary to record the date and time of ruxol itinib, and ARV  medicines for the 3 
days preceding  the week 4 study visit.  The medicati on diary will be collected at the week 4 
study visit.   
 
During these visits:  
 You will have a brief physical exam performed.  
 You will be asked about any new medications since your last visit including your HIV -1 
medications.  
 You will have 1 tablespoon  of blood drawn for rou tine safety blood tests, including lipid 
testing at week 5, and immune tests. At weeks 2, 5, and 12 study visits, blood will be drawn 
for CD4+ T cells c ount and viral load tests.  
 You will have approximately from 2 to 6  tablespoons of blo od drawn and stored for future 
protocol -related testing  (except at the week 1 v isit).     
   A5336 ( 05/21/15) 
FINAL  Version 2.0 
 APPENDIX I (Cont'd)  Page 4 of 10 
 
 Saliva and cells from your cheeks will be collected with an oral swab and tested for 
the presence of HHV . 
 If you are in Group A, a t week s 1 and 4 study visit s you wil l have about 2 tablespoons of 
blood drawn over 6-8 hours  to measure  ruxolitinib and ARV medicines levels in your blood.  
You will be contacted the night before each pharmacokinetic (PK) visit to remind you not to 
take your morning dose of ruxolitinib or ARV medicines (including efaviren z) until instructed 
during your clinic visit in the morning. You will be asked to bring your study drug and ARV 
medicines  to the clinic.  You will have blood drawn 4 times during this time period to 
determine the levels  of ruxolitinib and  ARV medicine s in your blood. For the multiple blood 
samples required, an indwelling catheter (a small, thin tube) will be put into an arm vein and 
left in place during your stay in the clinic  if preferred . An IV tube will be placed at the end o f 
the catheter for the PK blood draws.  This will allow the blood samples to be drawn without 
any additional needle sticks.  You may eat or drink as you wish during this period.  
 You will be asked questions about adherence to the study drug (Group A) and your ARV 
medicines . 
 
Virologic Failure  
If the study staff sees that your viral load has gone up, and there is no other known explanation 
such as the flu, you will be asked to have another test done within 7 days . If your viral load is 
still up and you are stil l taking study drug, you will be asked to stop the study drug  and come to 
the clinic within 2 weeks. You will be followed on study/off study treatment until the final study 
visit, week 12.  
 
Pregnancy  
If you become pregnant, study drug will be discontinued immediately , and you will be 
encouraged to remain in the study to be followed on study/off treatment until study completion . 
You will be followed by telephone contact thereafter to determine the pregnancy outcome . 
 
Premature Treatment/Study Discontinuation  
If you stop taking the study drug before the study -defined 5 -week treatment period, you will be 
asked to return to the clinic to complete some evaluations.  
 You will have a brief physical examination performed.  
 You will be asked about any new medications s ince your last visit including your HIV -1 
medications.  
 You will have approximately 6 tablespoons of blood drawn for routine safety blood tests  
including lipid panel , CD4+ T cells count, viral lo ad, immune tests  along with other tests. 
Also, some of your bl ood will be stored for future protocol -related testing.  
 Saliva and cells from your cheeks will be collected with an oral swab and tested for 
the presence of HHV . 
 If you are in Group A, y ou will have 2 tablespoons of blood drawn for measuring ruxolitinib 
and HIV -1 drug levels in your blood  if you are discontinuing study treatment  prior to week 4 . 
 You will be ask ed questions about adherence  to the study drug (Group A) and your ARV 
medicines .  
 
Other  
If you agree, some of your blood  that is left over after all  required study testing is done may be 
stored (with usual protectors of identity) and used for ACTG -approved HIV -1 related research. 
Please check the appropria te response if you agree to storing samples for future use . 
   A5336 ( 05/21/15) 
FINAL  Version 2.0 
 APPENDIX I (Cont'd)  Page 5 of 10 
 
Please indicate below “yes” or “no” a nd initial and date whether you approve the use of these 
stored samples. Note that you can withdraw your consent for research on stored specimens at 
any time you want and the specimens will be discarded.  
 
______________________  Yes, I agree.       ________ ____________  No, I do not agree.  
 
 
WHAT ARE THE RISKS OF THE STUDY?  
 
The drug used in this study may have side effects, some of which are listed below. Please note 
that this list does not include all the side effects seen with this drug. This list includes  the more 
serious , life-threatening  or common side effects with a known or possible relationship. If you 
have questions concerning the additional study drug side effects please ask the medical staff at 
your site. The most common side effects observed in th e past ruxolitinib clinical studies include:  
 
 Thrombocytopenia (decreased cells in the blood that are needed to stop bleeding)  
 Neutropenia (an abnormally low count of white blood cell s that help fight off 
infections)  
 Diarrhea  
 Fever  
 Urinary tract infections  
 Anemia  
 Bruising  
 Dizziness  
 Headache  
 Transaminase elevations  (increased liver enzymes that may indicate liver disease )  
 Cholesterol elevation  
 Infections  
  
It is not known whether the study drug passes through breast milk and whether it can produce 
adverse e ffects in the infant. Additionally, it is not known whether taking the study drug will 
reduce the risk of passing HIV to the baby while breastfeeding. You must tell the study doctor or 
nurse whether you are breastfeeding before enrolling in the study. You cannot participate in 
the study if you are breastfeeding.  
 
There is a risk of serious and/or life -threatening side effects when non -study medications are 
taken with the study drug. For your safety, you must tell the study doctor or nurse about all 
medicat ions you are taking before you start the study and also before starting any new 
medications while on the study. Also, you must tell the study doctor or nurse before enrolling in 
any other clinical trials while on this study.  
 
Risk of Blood Draw  
 
Taking blo od may cause some discomfort, bleeding, bruising, and/or swelling where the needle 
enters the body and in rare ca ses it may result in fainting. There is a small risk of infection.  
 
 
   A5336 ( 05/21/15) 
FINAL  Version 2.0 
 APPENDIX I (Cont'd)  Page 6 of 10 
 
Risk of Social Harm  
Although the study site will make every effort to pro tect your privacy and confidentiality, it is 
possible that others could find out that you are participating in this study and that social harms 
may result (because you could become labeled as being infected with HIV). For example, you 
could be treated unfa irly or discriminated against by family members, friends, and/or the 
community.  
 
 
HOW MANY PEOPLE WILL TAKE PART IN THIS STUDY?  
 
About 60 people will take part in this study  
 
 
HOW LONG WILL I BE IN THIS STUDY?  
 
You will be in this study for about 12 weeks.    
 
 
WHY WOULD THE DOCTOR TAKE ME OFF THIS STUDY EARLY?  
 
The study doctor may need to take you off the study early without your permission if:  
 
 You miss 2 visits in a row.  
 The study is canceled.  
 The study doctor or your regular d octor thinks the study is no longer in your best interest.  
 
The study d octor may also need to take you off the study drug without your permission if:  
 
 You have confirmed virologic failure  if you are in Arm A . 
 You miss more than 3 doses of study drug a week for at least two weeks.  
 You change or stop your anti -HIV-1 medicines  if you are in Arm A . 
 Continuing the study drug may be harmful to you.  
 You need a treatment that you may not take while on the study.  
 You are not able to take the study medicine as required by the study.  
 You becom e pregnant.  
 
If you must stop taking the study drug befor e the study is over, the study d octor may ask you to 
continue to be part of the study and return for some study visits and procedures.  
 
If you must permanently stop taking ruxolit inib before your st udy participation is over, the study 
staff will discuss other options that may be of benefit to you. After you have completed your 
study participation, the study will not be able to continue to provide you with ruxolit inib that you 
received on the study. I f continuing  to take this  or a similar drug/agent  would be of benefit to 
you, the study staff will discuss how you may be able to obtain ruxolitinib . 
 
 
 
 
   A5336 ( 05/21/15) 
FINAL  Version 2.0 
 APPENDIX I (Cont'd)  Page 7 of 10 
 
ARE THERE RISKS RELATED TO PREGNANCY?  
 
It is not known if the drug or drug combinations in this study harm unborn babies. If you are 
having sex that could lead to pregnancy, you must agree not to become pregnant  or make a 
woman pregnant.  
 
Because of the risk involved, you and your partner must use one form  of birth control that you 
discuss with the study staff. You must start one method of birth control when you are taking your 
study drug. You must con tinue to use this method until 7  weeks after you stop the study drug.  
 
 Condoms (male or female) with or without a spermicidal agent. Condoms are recommended 
because their appropriate use is the only contraceptive method effective for preventing HIV -
1  transmission.  
 Diaphragm or cervical cap with spermicide  
 Intrauterine device (IUD)  
 Hormone -based contraceptive  
 
If you can become pregnant, you must have a pregn ancy test before you enter this study. The 
test must show that you are not pregnant. If you think you may be pregnant at any time during 
the study, tell your study staff right away. The study staff will talk to you about your choices.  
Pregnancy will result  in immediate discontinuation  of the study drug  for the pregnant participant . 
You will be followed on study  until study completion  and will be followed by telephone contact 
thereafter to determine the pregnancy outcome. Pregnancies that occur on study will  be 
reported prospectively to The Antiretroviral Pregnancy Registry.  
  
 
ARE THERE BENEFITS TO TAKING PART IN THIS STUDY?  
 
This study is intended to gather information about how ruxolitinib acts on your immune system, 
not to treat your HIV -1 infection. There is no anticipated benefit for taking part in this study. 
Information learned from this study may help others who have HIV.  
 
 
WHAT OTHER CHOICES DO I HAVE BESIDES THIS STUDY?  
 
Instead of being in this study you have the choice of:  
 
 Treatment with prescri ption drugs available to you.  
 Treatment with other experimental drugs, if you qualify.  
 No treatment  
 
Please talk to your doctor about these and other choices available to you. Your doctor will 
explain the risks and benefits of these choices.  
 
 
 
 
 
   A5336 ( 05/21/15) 
FINAL  Version 2.0 
 APPENDIX I (Cont'd)  Page 8 of 10 
 
WHAT ABO UT CONFIDENTIALITY?  
 
We will do everything we can to protect your privacy. In addition to the efforts of the study staff 
to help keep your personal information private, we have gotten a Certificate of Confidentiality 
from the U.S. Federal Government. This certificate means that researchers cannot be forced to 
tell people who are not connected with this study, such as the court system, about your 
participation. Also, any publication of this study will not use your name or identify you 
personally.   
 
People w ho may review your records include the ACTG, Office for Human Research Protections 
(OHRP) or other government agencies as part of their duties, Food and Drug Administration  
(FDA), (insert name of site) I nstitutional Review Board (IRB)  (a group that protect s the rights 
and well -being of people in research), National Institutes of Health (NIH), study staff, study 
monitors, and their designees. Having a Certificate of Confidentiality does not prevent you from 
releasing information about yourself and your parti cipation in the study.  
 
Even with the Certificate of Confidentiality, if the study staff learns of possible child abuse and/or 
neglect or a risk of harm to yourself or others, we will be required to tell the proper authorities.  
A description of this clinic al trial will be available on www.ClinicalTrials.gov , as required by U.S. 
law. This Web site will not include information that can identify you. At most, the Web site will 
include a summary of the results. You  can search this Web site at any time.  
 
 
WHAT ARE THE COSTS TO ME?  
 
Taking part in this study may lead to added costs to you and your insurance company. In some 
cases it is possible that your insurance company will not pay for these costs because you are 
taking part in a research study. There will be no cost t o you for study drug , study -related visits, 
physical examinations, laboratory tests, or other study procedures. Note that ARV medicines will 
not be provided by the study.  
 
 
WILL I RECEIVE ANY PAYMENT?  
 
You will be compensated for participating in the study  regardless of the group you were 
assigned to . 
 
 
WHAT HAPPENS IF I AM INJURED?  
 
If you are injured as a result of being in this study, you will be given immediate treatment for 
your injuries. The cost  for this treatment will be charged to you or your insurance company. 
There is no program for compensation either through this institution or the National Institutes of 
Health. You will not be giving up any of your legal rights by signing this consent form . 
 
 
 
 
   A5336 ( 05/21/15) 
FINAL  Version 2.0 
 APPENDIX I (Cont'd)  Page 9 of 10 
 
WHAT ARE MY RIGHTS AS A RESEARCH PARTICIPANT ? 
 
Taking part in this study is completely voluntary. You may choose not to take part in this study 
or leave this study at any time. Your decision will not have any impact on your participation in 
other stu dies conducted by NIH and will not result in any penalty or loss of benefits to which you 
are otherwise entitled . 
 
We will tell you about new information from this or other studies that may affect your health, 
welfare, or willingness to stay in this study.  If you want the results of the study, let the study staff 
know.  
 
 
WHAT DO I DO IF I HAVE QUESTIONS OR PROBLEMS?  
 
For questions about this study or a research -related injury, contact:  
 
 name of the investigator or other study staff  
 telephone number of above   
 
For questions about your rights as a research participant , contact:  
 
 name or title of person on the Institutional Review Board (IRB) or other organization 
appropriate for the site  
 telephone number of above  
 
   A5336 ( 05/21/15) 
FINAL  Version 2.0 
 APPENDIX I (Cont'd)  Page 10 of 10 
 
SIGNATURE PAGE  
 
If you have read this consent form (or had it explained to you), all your questions have been 
answered and you agree to take part in this study, please sign your name below.  
 
 
 
____________________________  ________________________________________  
Participant’s Name (print)  Participant’ s Signature and Date  
 
 
____________________________  ________________________________________  
Participant’s Legal Representative (print)  Legal Representative’s Signature and Date  
(As appropriate)  
 
 
____________________________  ______________________________ ___________  
Study Staff Conducting  Study Staff’s Signature and Date  
Consent Discussion (print)  
 
 
____________________________  _________________________________________  
Witness’s Name (print)  Witness’s Signature and Date  
(As appropriate)  